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ABSTRACT OF THE DISSERTATION
Mechanisms of Extracellular Vesicle Biogenesis
by
Charles E. Jackson
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2016
Dr. Phyllis I. Hanson, Chair
Dr. Robert Mecham, Co-Chair
Extracellular vesicles (EVs) are important mediators of intercellular communication.
Different types of EVs are released from cells by either fusion of late endsomal multivesicular
bodies with the plasma membrane (exosomes) or direct budding from the plasma membrane
(ectosomes). Topologically equivalent processes including intralumenal vesicle formation for
degradation in the endosomal pathway and virus budding from the plasma membrane depend on
the ATPase VPS4 and its Endosomal Sorting Complex Required for Transport (ESCRT)-III
substrates for membrane fission and release. Whether this machinery is generally required for
EV biogenesis has, however, been the subject of debate. Studies of the EV proteome from a
variety of cell types consistently find ESCRT-III subunits, thus providing further impetus for
studying their function in EV biogenesis. Detailed understanding of the mechanisms underlying
EV biogenesis is critical to testing their proposed functions. Monitoring EV release, however,
remains technically challenging. To this end, I developed a protocol for efficiently isolating EVs
from small numbers of cultured cells. Using this together with complementary standard
techniques, I found that inhibiting VPS4 reduced release of both protein and miRNA in EVs.
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Notably, VPS4 activity was required for the release of two proteins – the tetraspanins CD63 and
CD9 – that preferentially reside on different membranes and are enriched on separate EV
populations. I establish that CD63 is enriched on and preferentially marks endosome-derived
exosomes while CD9 is a primary marker of plasma membrane-derived ectosomes. An
important question in the cell biology of exosome release is what distinguishes exocytic from
degradative MVBs. I identified Rab27b as a selective marker of a subset of less acidic and likely
exocytic MVBs. Neutralizing endosomal pH increased Rab27b recruitment to CD63 containing
MVBs, pointing toward an important role for pH in regulating Rab27b recruitment. Returning to
the role of VPS4 and ESCRT-III, our data broadly implicate VPS4 and ESCRT-III in biogenesis
of both exosomes and ectosomes. I established cell lines expressing fluorescent CD63 and CD9
singly or in combination in order to further probe their segregation to different EV populations.
Intriguingly, inhibiting VPS4 increased the concentration of ESCRT-III protein recovered in EVs
despite the significant decrease in total vesicle release. This suggests a role for ESCRT-III
disassembly during EV fission. Altogether, the work presented here sets the stage for future
studies aimed at understanding multiple aspects of exosome and ectosome biogenesis.
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Chapter 1
Introduction
1.1

Overview: What is an extracellular vesicle?
Extracellular vesicles (EVs) are secreted from cells as sub-micron sized spherical mosaic

lipid bilayers that contain transmembrane and peripherally associated membrane proteins. The
vesicles encapsulate both soluble proteins and nucleic acids. EV topology is like that of the cell
that produced it: the vesicle lumen is comprised of cytosol, and proteins at the surface are in the
same orientation as at the plasma membrane. Hence, EVs can be thought of as nano-organelles
that, like cells, are capable of interacting with the environment and with other cells. Knowledge
about these interactions is still growing, but it has become clear since the first descriptions of EV
expulsion nearly 50 years ago that these organelles have broad functions in intercellular
communication.
The ability of cells to release EVs appears to be an evolutionarily conserved
phenomenon. They have been described in a variety of multicellular organisms, such as
Drosophila Melanogaster and Caenorhabtitis Elegans (1, 2). Single-celled fungi and even
archaebacteria have been shown to release EVs (3-5). Studies performed in these systems
generally corroborate mechanisms of EV biogenesis and EV functions found in human cells (68). These findings highlight the ubiquity and evolutionary conservation of EV release and
provide strong evidence supporting their physiologic importance.
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EVs are found in many human bio-fluids including blood, saliva, urine and cerebral
spinal fluid to name a few (9-11). Since virtually all cell types investigated to date secrete EVs, it
is likely that body fluid EVs derive from multiple origins. Several proteins are common to EVs
released by all cells, while others are uniquely associated with the secreting cell. In addition,
even a single cell can produce different types of EVs that derive from different intracellular
membranes. Thus, all EV source fluids contain heterogeneous mixtures of EV types. This EV
heterogeneity is a major factor complicating investigation of EV functions and mechanisms of
biogenesis. A great deal of attention has recently been placed on efforts to identify molecules
that are representative of different EV classes. The following chapter provides a broad overview
of extracellular vesicle biology placing emphasis on what is known about formation and function
of different vesicle populations, in particular exosomes and ectosomes.
1.1.1

Cells release different types of EVs
In 1967, membranous particles termed “platelet dust” were probably the first described

EVs. They possessed coagulation properties similar to those of the platelets from which they
derive (12). The term prostasome was coined some years later to describe small prostate
epithelia-derived vesicles found in seminal fluid (13). More recently, vesicles shed by tumor
cells have been referred to as oncosomes (14). These are a few examples of cell-type specific EV
descriptions. While EV content and function differ among cell types, all cells appear able to
release two general types of EVs as defined by their intracellular membrane of origin (Figure 11). Exosomes bud into the lumen of endocytic multivesicular bodies (MVBs) and are expelled
from the cell upon MVB fusion with the plasma membrane. Ectosomes, in contrast, are released
in a single step by budding directly from the cell surface. The fact that different EV populations
are released from a single cell raises the question of whether these different EV types play
distinct functional roles. Differing subcellular distribution of EV cargo correlates with the mode
2

by which it is released, and manipulations that affect both subcellular distribution and release
strengthen such claims. However, identifying clear markers of either EV class remains a major
challenge (15-17).
1.1.2

Current Methods of Investigating EVs
The list of available approaches for analyzing EVs has expanded in recent years. Global

EV–omics studies provide a broad picture of EV content and lead to assays that directly monitor
a cargo of interest. Cell imaging reveals details about cargo molecule trafficking and EV release.
Particle analyses provide information about EV size, number and concentration. The following
discussion reviews the current state of methodologies used for EV research.
Assessing quality of EV preparations—The International Society of Extracellular
Vesicles recently published a minimal set of criteria to guide distinction between EV and nonEV material (18). These guidelines are meant to help standardize what is described as an EV
(rather than distinguishing among different types of EVs, e.g. exosomes vs. ectosomes). The first
criterion logically requires that the EV material is isolated from extracellular fluid. Second, the
need to identify proteins enriched in EVs compared to the EV-producing cells is highlighted.
Examples of such proteins include integral membrane proteins, such as the tetraspanins, and
cytosolic proteins that are known to interact with receptors or with membranes giving rise to EVs.
In addition, intracellular proteins that reside in organelles from which EVs do not arise (e.g.
Golgi, ER or nucleus) are expected to be de-enriched in EV preparations. The final criterion
considered is some type of single vesicle analysis. Both direct visualization (e.g. transmission
electron microscopy, high resolution fluorescence microscopy) and diffusion-based technologies
(e.g. dynamic light scattering, nanoparticle tracking) can provide overviews of the size
distribution of EVs.

3

Isolating EVs—EVs can be isolated using several methods that are generally based on
either size or content. These methods provide a range of specificities, yields and purity.
Comparative analyses demonstrate these differences, and different methods can be combined to
separate EVs with different properties. To date, there is no robust method for physical separation
of exosomes and ectosomes, in part because of the overlap between plasma membrane and
endosomal membrane content.
Differential centrifugation is the most common method for isolating EVs from a variety
of source fluids. The basis for vesicle separation is size. Typically, extracellular fluids are subject
to an initial clearing step in which cells and large debris are sedimented at low g-force. Micronsized vesicles are then sedimented at a range of 10,000-12,000 × g. A filtration step is often
added to clear particles above a size range of 200-500nm. Finally, smaller vesicles are
sedimented by prolonged centrifugation at 100,000-110,000 × g. In some cases, this protocol is
modified to pellet micro- and nano-vesicles together. Differential centrifugation is capable of
isolating vesicles for a variety of downstream applications. Among these are immunoblotting,
RT-PCR, imaging by optical methods or electron microscopy, mass-spectrometry and cell uptake
assays. A major downfall of differential centrifugation is the requirement for large volumes of
source fluid (19). High yields can be obtained by increasing the source volume, but even then
recovery efficiency is often only moderate (20). Furthermore, non-EV material including protein
aggregates and lipoproteins can co-sediment with EVs isolated by this technique. Still,
differential centrifugation is the current method of choice for collecting EVs and is an acceptable
standard when coupled with stringent characterization of the pelleted material. Based on the
average ILV size in mammals (~50nm), 40-150nm diameter vesicles are often considered to be
exosomes (21). Vesicles larger than ~150nm are assumed to originate from the plasma
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membrane and are referred to variously as microvesicles or ectosomes. Notably, however,
smaller ectosomes are not readily distinguishable from exosomes using standard techniques, and
it is likely that EVs prepared by differential centrifugation contain a mixture of vesicle types.
Density equilibrium floatation is widely used to demonstrate that a particular secreted
molecule is associated with EVs. Applying the gradient over the sample allows buoyant
membrane and membrane-associated molecules to float to equilibrium leaving behind soluble
contaminants. This is in contrast to density equilibrium sedimentation, in which the sample is
applied to the top of the gradient. Density equilibrium floatation can also distinguish among
vesicles with different buoyant properties (22). A sucrose density between 1.15 and 1.19 g/ml is
characteristic of exosomes based on the fractionation of proteins such as CD63, ALIX and
TSG101 known to be associated with MVBs. Once again, however, the presence of ectosomes
with similar protein content cannot be ruled out. EVs larger than 150nm exhibit higher densities
(23), and proteomic analysis revealed that these larger EVs uniquely associate with extracellular
matrix components and are likely to originate from the plasma membrane.
Affinity purification isolates EVs based on the presence of defined molecule(s) on their
surface. Therefore, this method is ideal for characterizing specific EV sub-classes. EVs collected
by immuno-affinity isolation have been used for downstream applications such as
immunoblotting, fluorescence cytometry and mass spectrometry. Comparative analyses
demonstrate that immuno-affinity isolation exhibits superior efficiency and purity compared to
differential centrifugation and density floatation (24). Several commercial kits are available for
immuno-capture, and this approach is an obvious choice for developing clinical diagnostic
applications. Known differences in intracellular localization (e.g. endosomes vs. plasma
membrane) can be a predictor for identifying proteins released on distinct types of vesicles.
5

Proteomic studies of immuno-affinity purified EVs has provided insight into the composition of
different EV populations (25,23).
EVs can be concentrated based on size using membrane filters with micron-sized pores
that retain EVs with diameters larger than the pores. Recently, EVs produced by LIM1863 cells
were fractionated by sequential filtration through PVDF membranes with pore sized ranging
from 0.65µm to 0.1µm (26). The authors found only two EV size classes. EVs ~300-1000nm
were retained by the largest pore size filter, and EVs ~30-100nm remained in the filtrate after
passage through the smallest pore size. EM and dynamic light scattering confirmed the size of
EVs in each fraction. Limitations to this approach include an inability to separate EVs from large
proteins and aggregates and difficulties recovering EVs from the surface and/or pores of the
filter.
Size exclusion chromatography (SEC) is another approach that has been used to isolate
EVs (20, 27, 28). Vesicles isolated by this method are relatively pure but a second step (either
centrifugation or filter-based concentration is needed) to concentrate EVs for most downstream
applications. The ensuing losses limit the efficiency of this isolation protocol.
Quantifying EVs—Methods to quantify EVs are necessary in order to study their biology
and gain insight into the factors involved in EV release. An early and general approach is to
determine the total protein concentration in EV isolates, but this provides no information about
changes in protein composition or vesicle numbers (19). Immunoblotting for EV proteins is
commonly employed to assess changes in the protein profile of EV isolates. However, changes in
the number of EVs can only be inferred. The following section discusses methods for directly
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counting EVs. Each has limitations and advantages, and it is clear that new approaches are still
needed.
Direct visualization allows distinction between individual membrane vesicles and other
types of particles such as large protein aggregates. Electron microscopy has been the choice
method for observing EVs because of their small size. Immunolabeling coupled with EM can
provide information about protein distribution (29). EM can also provide an estimate of the size
range of EVs obtained by a given isolation procedure. It is not, however, suitable for counting
EVs.
Dynamic light scattering is an optics-based method for determining the size and number
of particles in suspension. A laser illuminates a volume of the medium, and the particles present
in suspension scatter light in a pattern that depends on their size, shape and molecular
interactions (30). Fluctuations in light scattering occur over time due to particle movement.
These measurements are used to generate a mathematical model of the change in scatter over
time (the autocorrelation function), which can then be used to extrapolate particle size and
number. The extrapolated parameters are an average computed from the contribution of all of the
particles present in the illuminated volume. Scatter intensity depends on size, leading to a
skewing of results toward larger particles. Thus, the polydispersity of most EV preparations
(including non-EV particles) limits the utility of this approach for describing the size distribution
of EVs.
Nanoparticle tracking analysis (NTA), in contrast to dynamic light scattering, is an
optical method for determining particle size and number that is independent of light scatter
intensities. A time-lapse series of images of particles moving under Brownian motion is used to
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track individual particles. Size information for each particle is extrapolated from its movement,
and particle concentration is determined by particle counts within the defined illumination
volume. As with dynamic light scattering, NTA detects all light-scattering particles and therefore
requires pure EV preparations. This limitation can be overcome by using fluorescent probes that
selectively label EVs (31). The simplicity and rapid read-out of NTA makes this an appealing
technology for both research and clinical applications.
Flow cytometry (FC) is another technique used to quantitate EVs. Early applications of
this technique coupled EVs to micron-sized beads to increase particle size thereby allowing
detection (29, 32). Importantly, this approach cannot provide information about EV size or
absolute number. Conventional FC measuring forward and side light scatter can only resolve
objects larger than 500nm, and is thus not appropriate for detecting smaller sized EVs. Recent
advances in FC technology are enabling EV analysis by measuring light scattered at larger
angles, using smaller probe volumes and slower flow rates (33). A major advantage to this
approach is the ability to distinguish EVs from other particles by using fluorescence labeling
with antibodies or lipophilic dyes. However, size estimation in this paradigm is hampered by
lack of knowledge about number of labeled molecules per EV, which directly contributes to
fluorescence intensity. It is worth noting that accurate size estimation also requires calibration
standards (such as synthetic beads) with size and refractive indices similar to EVs (34). The
sensitivity of FC toward the smallest of EVs is still a concern.
Resistive pulse sensing is another approach used to monitor the size and number of EVs,
and works by detecting the movement of single particles through a pore. The pore is in a
membrane across which a voltage is applied to create a current. Increases in resistance as the
particles move through the pore and the frequency of resistance increases are used to estimate
8

particle size and number, respectively (34-36). In one study, the lower size limit of EV detection
was ~50nm, but smaller EVs were readily observed in EM preparations (34). Pore clogging
remains a major technical challenge, and pure EV preparations are needed since this method
cannot distinguish between EVs and other EV-sized particles.
Monitoring EV release from cells—Direct observation of EV release is a major challenge
in the field since the small size of EVs presents a challenge for conventional microscopy due to
diffraction limits. Discriminating a release event among the behaviors of the entire population of
organelles and domains labeled by a given marker is challenging even with sensitive highresolution imaging. Attempts to address this obstacle include the use of total internal resonance
fluorescence microscopy (TIRFM) to demonstrate delivery to and docking of MVBs to the
plasma membrane (32). In the future, TIRFM could also provide an approach for monitoring
ectosome release in a similar fashion to studies on HIV budding (37,38).

1.2

EV functions
EVs represent a unique intercellular communication system potentially capable of

delivering hydrophobic and soluble cargo to influence signaling and other processes in cells both
near and far. Their original and still best-studied functions are in the immune system, where
exosomes participate in antigen presentation and stimulating immune responses (16). However,
EVs have now been implicated as central players in progression of diseases as heterogeneous as
metastatic cancer (39-42), neurodegeneration (43, 44) and autoimmune disorders (45). A few
examples of recently defined roles are in breast cancer progression and therapy resistance (46),
trophic support to neurons (47), transmitting pathogenic prions in the brain (44), and disposal of
cholesterol in lysosomal storage disease (48). The potent but in many cases varied effects
attributed to EVs provide strong justification for future experimentation in disease models and
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suggest exciting therapeutic applications. The following section provides a brief discussion of
the physiologic functions attributed to EVs. In addition, a recently proposed function for EVs in
virus-independent propagation of viral genomic material is highlighted.
Cellular remodeling via EV release—Exosomes were initially described as a mechanism
for eliminating membrane proteins employed by maturing reticulocytes (49, 50). During the
maturation process, these erythroid precursors become enucleated, and unnecessary proteins are
selected for mass exodus. Early studies demonstrated that transferrin receptor is internalized
from the cell surface and sorted to MVBs before being exocytosed on exosomes. The in vivo
relevance of this pathway is evidenced by the delayed reticulocyte maturation, accumulation of
transferrin receptor and microcytic anemia exhibited by mice that are deficient in p53-regulated
exosome secretion (51). The α4β1 integrin is cleared from reticulocytes via exosomes
implicating them in down-regulation of cellular adhesive properties (52). These studies delineate
exosome secretion as an alternative lysosome-independent means to control protein and
cholesterol levels.
More recently, changes in cellular content brought about by EV secretion have been
suggested for other cell types. Ectocytosis is proposed to regulate levels of the GPI-anchored
CD24 receptor during B-cell maturation (53). Both cadherin and β-catenin are released in EVs in
a manner that depends on expression of CD9 and CD82 tetraspanins (54). Thus, EVs may
regulate Wnt signaling through modulating cellular levels of β-catenin. EVs can also modulate
signaling in an autocrine fashion through polarized release of receptor ligands. For example,
tumor cell intravasation occurs through directional movement that requires extracellular matrix
degradation. Invadapodia are actin-based protrusions that facilitate this process, and these
structures are hot spots for EV release (55). Matrix metalloproteases are EV cargos that promote
10

matrix clearance (56). Ligands such as fibronectin associate with the surface of EVs and may
promote directional tumor cell movement (57). Thus, polarized release of EVs by tumor cells
could literally pave the way for intravasating cells by clearing matrix and laying out a substrate
across which the cell can traverse.
Immune regulation—The most well characterized function of EVs is modulating immune
responses. EVs released from myriad cell types carry molecules that are involved in activation or
suppression of immune cells. It is clear that changes in the molecular composition of EVs are
able to dictate the type of response. Such changes correlate with the status of the EV producing
cell. For example, EVs can announce exposure to microbial pathogens, and oncogenic
transformation can quell EV immune-activating properties. The ability of EVs to transfer
information over long distances compared to soluble secreted proteins allows broader
surveillance of physiologic status. The contribution of EVs to immune biology has provided a
foundation for several clinical trials utilizing EVs for therapeutic purposes (58).
The observation that EVs released by B-cells are capable of activating T-cells was a
pivotal finding that launched studies leading to the current understanding of EVs as important
mediators in intercellular communication (59). Since this discovery, it has become clear that
other antigen presenting cells (dendritic cells; DCs and Macrophages; Macs) release EVs with
similar properties. These cells capture and process foreign antigens for presentation on MHC I or
II molecules upon activation. Peptide-MHC and co-stimulatory molecules are then released on
EVs (59-61). Evidence suggests that T-cell priming by bystander antigen presenting cells is
required for EV-mediated activation (62,63). While the source of antigen can be through direct
contact of antigen presenting cells with pathogens, EVs can deliver antigens to immature
antigen-presenting cells thereby potentiating T-cell activation. Antigen-exposed B-cells travel to
11

the spleen where DCs take up antigen for presentation to T-cells – a process that may be
facilitated by B-cell EVs (64). Nonhematopoietic cells can also provide antigen-loaded EVs. For
example, EVs from intestinal epithelium carry peptide-MHC II complexes that can transfer to
DCs (65,66).
Immunosuppressive functions can convey immune privilege to the developing fetus as
well as to tumors (67, 68). EVs derived from trophoblast cells are found in the uterine fluid and
the blood of pregnant women. Similarly, EVs with tumor cell associated molecules are found in
the circulation of individuals with cancer (69). In each case, immune modulation involves
suppression of T-lymphocytes. Natural killer cell cytotoxicity is inhibited by EVs that engage
NKG2D receptors via peptide-MHC I or truncated MHC I during pregnancy and cancer (70)(71).
Furthermore, EVs from trophoblast and tumor cells carry FasL/TRAIL molecules that induce Tcell apoptosis (67, 72). Recent evidence points towards bi-directional EV-mediated
communication during pregnancy (73). The authors found that trophoblast cells take up EVs
from Macs, which results in increased secretion of IL-6, IL-8 and IL-10 cytokines. This finding
implicates EVs as a mechanism by which the maternal immune system can communicate
inflammatory conditions to the developing fetus. Whether the altered cytokine production in
response to Mac EVs culminates in anti- or pro-inflammatory responses remains an open
question. Given the parallels between EV-mediated communication during pregnancy and cancer
it will be interesting to see if future studies reveal a role for immune cell EVs in altering tumor
phenotypes. Taken together, the studies outlined here demonstrate that EVs play a critical role in
immune surveillance and highlight a few of what are likely to be many dynamic responses
mediated by EVs.

12

Viral genome transfer—EV contents include protein and nucleic acid cargo that can be
transferred between cells via these vesicular shuttles. Notably, cells that are infected with
bacterial or viral pathogens incorporate pathogen-derived molecules into their EVs (74,75). The
role of this phenomenon in activating immune responses to combat infection is discussed in the
previous section. Importantly, viruses can also highjack EVs in order to transfer molecules to
uninfected cells thus manipulating their environment and allowing for their propagation. Such is
the case for HIV, which induces apoptosis of uninfected cells through EV-mediated transfer of
negative regulatory factor (76). The transfer of virus-derived molecules, including nucleic acids,
further raises the question of whether EVs provide a mechanism by which viruses transfer their
genome but remain undetected by the host immune system. This is particularly intriguing given
that many viruses undergo latency periods during which they remain apparently dormant before
viral loads rapidly increase. Several studies suggest EV-mediated infection mechanisms, but the
similar size and biophysical properties of EVs and viruses make them difficult to separate and
complicate investigation into this process (77, 78). In a recent study, Longatti and colleagues
suggest that Hepatitis C viral RNA can transfer from cells incapable of forming viral particles
(79). It will be interesting to see if future studies will confirm EV-mediated transfer of viral
genomes and if this process extends to other types of viruses.

1.3

EV biogenesis
As discussed above, EVs are released through either fusion of MVBs with the plasma

membrane (exosomes) or through direct budding of the plasma membrane (ectosomes). A host of
factors have been described to regulate the initial steps of cargo sorting and membrane fission
that are required to generate both exosomes and ectosomes. Some of these are unique to a
specific EV type, while others are required for both. These mechanisms are discussed together in
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sections 1.3.1 through 1.3.4. In contrast to ectosomes, exosome production involves a second
obligate step: fusion of the MVB with the plasma membrane. The factors involved in this process
are discussed in section 1.3.6.
1.3.1

ESCRT1
ESCRT complexes are modular but interconnected entities that most clearly act at the

MVB to recognize and concentrate cargo, facilitate membrane deformation to initiate vesicle
formation, and finally constrict vesicle necks to drive membrane scission. The modular nature of
the ESCRT machinery provides flexibility in how their function can be harnessed to accomplish
a range of activities. Models for how ESCRTs operate in MVB biogenesis as well as the
topologically related processes of viral particle release and cytokinesis are explored in a number
of reviews written over the past few years (80-83).
ESCRT proteins and the complexes they form are soluble and associate transiently with
membranes, similar to other membrane trafficking and remodeling factors. In their best known
role – delivering cargo protein into the vacuole or lysosome – ESCRT complexes can be divided
into those that cooperatively bind ubiquitin, phosphatidylinositol 3-phosphate, and each other to
recruit cargo and initiate membrane deformation and vesicle formation on the endosomal
membrane (ESCRT-0, -I, and –II) and those that complete the release of vesicles into the MVB
(ESCRT-III and Vps4). The numbering of the ESCRT complexes is based on the order in which
they are recruited for vacuolar protein sorting in yeast although, as will be apparent in the
following discussion, these are modular complexes that function in different combinations
depending on the system involved. A brief description of ESCRT complexes follows. Excellent

1

Hanson P. I., Jackson C. E., 2015. ESCRTing around the cell. Encylopedia of Cell Biology 2: 466-474.
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in-depth reviews discussing ESCRT complex structure and organization can be found in (82, 8486.
Early acting ESCRTs—ESCRT complexes implicated in cargo recognition and early
stages of ILV formation include ESCRT-0 (composed of Vps27/Hrs and Hse1/STAM), ESCRT-I
(composed of Vps23/Tsg101, Vps28, Mvb12 and Vps37), and ESCRT-II (composed of
Vps36/EAP45, Snf8/EAP30 and Vps25/EAP20). Each of these complexes is a constitutive
heterooligomeric complex and depletion of any single subunit destabilizes the whole complex.
Important features of these early acting complexes include a number of low-affinity ubiquitinbinding motifs for cargo recognition (all three), phosphatidylinositol 3-phosphate binding sites
for endosomal targeting (ESCRT-0 and ESCRT-II), and specific motifs that connect the
complexes to each other and in the case of ESCRT-II to ESCRT-III. Other factors able to engage
and activate ESCRT-III can replace some or all of these early acting ESCRT complexes,
expanding the repertoire of molecular pathways into the MVB. The best studied of these are
Bro1-domain containing proteins such as Alix that (like the early acting ESCRT complexes) bind
both ubiquitin and CHMP4 family ESCRT-III proteins (87-89).
ESCRT-III & Vps4—ESCRT-III and its AAA ATPase Vps4 are the central players in
ESCRT-driven membrane scission. The overall structure of individual ESCRT-III proteins (9092) and the filamentous assemblies they form is established (93, 94). A number of models
describing how rings and spirals on the membrane might facilitate membrane remodeling and
scission have been proposed and are discussed further below. There are seven non-redundant
ESCRT-III or ESCRT-III related proteins in the yeast Saccharomyces cerevisiae and twelve in
humans, and a varying but generally similar complement in other eukaryotes. All are predicted to
share a core molecular structure in which a helical hairpin is surrounded and regulated by short
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C-terminal helices (90, 91). ESCRT-III proteins cycle between a closed or autoinhibited
conformation in the cytoplasm and an open or activated conformation on the membrane that is
primed for polymer assembly (95-97). ESCRT-II and Alix bind ESCRT-III proteins to initiate
ESCRT-III polymer assembly. ESCRT-III then grows in a process for which mechanisms
controlling composition and final size have yet to be defined. Assembled ESCRT-III polymers
are intrinsically stable but because of Vps4-driven disassembly are short-lived in the cell (93,
98). Studies using RNAi to examine roles for individual ESCRT-III proteins support a general
conclusion that particular ESCRT-III proteins are more or less essential in different settings. A
general requirement for one protein related to Snf7/CHMP4 and one related to Vps2/CHMP2
appears to be conserved in most membrane remodeling processes (99). The reader is referred to
original descriptions of ESCRT-III polymers cited above and previous reviews for additional
details (81, 83, 100).
ESCRT and EVs—How involved the ESCRT machinery is in exosome (and more broadly
EV) biogenesis is still an open question. Because of the topology of EV formation (budding
away from the cytoplasm), an early and logical hypothesis was that EV formation would utilize
the same machinery responsible for creating ILVs within MVBs en route to degradation; i.e. the
ESCRTs. Proteomic studies abound in EV research, and many such studies identify ESCRT
proteins as components of the EV proteome (101, 102). In fact, Tsg101 (ESCRT-I) and Alix are
among the most common markers used to identify EVs (103). Despite interest in the role of the
ESCRT machinery in EV biogenesis, it has remained unclear if ESCRT function is generally
required for EV biogenesis. Seemingly straightforward experimental tests in different systems
provide contradictory results (29, 104-106) leading to the idea that at least some EVs may be
created without the help of ESCRTs (107, 108). However, while lipids clearly affect EV
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biogenesis (104), ESCRT-independent pathways for controlling EV formation have not emerged.
In fact, proteins recently implicated in EV biogenesis have each revealed new connections to the
ESCRT machinery. In one example, the adaptor protein syntenin-1 binds syndecans and other
transmembrane proteins and promotes their release in exosomes by recruiting Alix and ESCRTIII (106, 109). In another example, the arrestin domain protein ARRDC1 interacts with Tsg101
and ubiquitinated proteins at the plasma membrane to stimulate EV formation and release (110).
A number of reports indicate that perturbing ESCRT function can affect EV number, content, or
size (106, 110). Electron microscopy of artificial immunologic synapses showed that dominantnegative Vps4 inhibits release of ectosomes at the plasma membrane (111). Our finding that
ESCRT spirals accumulate on the plasma membrane in Vps4 depleted cells suggests the
possibility of similar release from other cultured cells (93). Further understanding of how the
ESCRT machinery contributes to generating EVs will aid in developing tools to manipulate EV
biogenesis.
1.3.2

Tetraspanins
Tetraspanins are small four-pass integral membrane proteins that organize protein

networks to facilitate diverse processes such as receptor signaling, protein trafficking, cell
adhesion and cell-cell fusion (112, 113). CD9, CD63 and CD81 are the most common
tetraspanins identified in EVs and have broad tissue distribution in mammals (114). The roles
tetraspanins play in EV biogenesis have been the subject of ongoing studies but still remain
enigmatic. Some cargos depend on tetraspanins for incorporation into EVs. CD9 regulates the
sorting of the CD10 metalloprotease in a manner that depends on the CD9 C-terminal tail (115).
Furthermore, CD9 but not CD82 regulates β-catenin EV sorting (54). Knockout of CD81
diminishes secretion of several CD81 interaction partners in EVs (116). Melanocytes contain
specialized secretory MVBs where the amylodogenic pigment cell-specific type I integral
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membrane protein (PMEL) is sorted before secretion onto intralumenal vesicles. This sorting and
release is reduced by CD63 depletion (105, 117).
How tetraspanin-based protein networks are organized is likely to be central to their
functions in EV biogenesis. Tetraspanins consist of two extracellular loops and two short
intracellular tails. The second larger extracellular loop is comprised of three clustered α-helices
that are stabilized by disulfide bonding. This extracellular loop interacts with the extracellular
regions of other proteins such as immunoglobulins, integrins and proteases (112). Cytoplasmic
N- and C- terminal tails of tetraspanins interact with intracellular adaptor proteins to link them to
signaling platforms and regulate their trafficking (113). Intracellular membrane-proximal
cysteine residues are palmitoylated (118). This palmitoylation is important for oligomerization,
interaction with partner proteins, protein stability (118-124).
Tetraspanins float in sucrose gradients when cells are homogenized with mild detergents
revealing their propensity to form tetraspanin-enriched microdomains (TEM) (125). Tetraspanin
interactions with other tetraspanins are typically preserved under these conditions. More
hydrophobic detergents disrupt them, but preserve tetraspanin association with non-tetraspanin
proteins. These observations have led to models of TEM organization whereby specific
tetraspanins bind avidly to non-tetraspanin partners and form less stable associations with other
tetraspanin complexes (126). Such organization is directly observed by cryo-electron microscopy
of urothelial plaques, in which a pair of specialized tetraspanins forms stable hexagonal
structures with a pair of type-I membrane proteins (127). Each tetraspanin binds tightly to a
specific partner, and these heterodimers associate through tetraspanin-tetraspanin interactions
(112, 127). In more recent studies, super-resolution analysis of TEMs in the plasma membrane
showed that the tetraspanin CD53 remained largely segregated from the tetraspanins CD37,
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CD81 and CD82 calling into question whether TEMs are primarily formed by interactions
between the same or different tetraspanin species (128).
Despite the evidence implicating tetraspanins as important components of EV structure
and composition, it is not known if and how TEM formation contributes to EV biogenesis.
Details about TEM dynamics and intracellular trafficking are needed to understand how TEMs
form and interact with each other and with other TEM protein constituents. Much of what is
known about TEM dynamics comes from studies at the plasma membrane. Therefore, TEM
organization on intracellular membranes is a topic of great interest.
1.3.3

Lipids
Combinations of different lipid species segregate into separate fluid phases in vitro (129-

131). In the cell, this property is important for the formation of membrane domains with
compositions and physical properties distinct from the surrounding bilayer. Membrane proteins
are laterally organized within these domains through their affinity for specific lipids and for other
proteins within the domain. Lipids are also important second messengers in signaling pathways
that regulate membrane trafficking. As such, lipids and lipid metabolism play essential roles in
the biogenesis of both exosomes and ectosomes.
Lipidomics studies have revealed a set of lipids that are typically enriched in EVs.
Among these are sphingosine-based species such as sphingomyelin, gangliosides and ceramide
(104, 132-134). Cholesterol is also enriched in EVs, and represents almost half of the total lipid
in PC-3 cell EVs (134). Manipulating cholesterol levels causes changes in EV release (48). EVs
released during different stages of reticulocyte maturation maintain constant cholesterol levels
while sphingolipids vary (135). These observations are in line with the notion that cholesterol
plays an important role in EV architecture. Sphingolipids and cholesterol comprise a major
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component of lipid raft domains in the cell. Like TEMs, lipid rafts are detergent-resistant
microdomains. Accordingly, B cell EVs exhibit degrees of detergent resistance (132).
Cholesterol is an important component of both TEMs and lipid rafts (136). Imaging studies such
as antibody co-patching, FRET and single-molecule labeling demonstrate segregation of TEMs
and lipid rafts (124). In contrast, there is evidence that TEMs and lipid rafts interact during HIV
budding (137). How this phenomenon contributes to viral maturation is unknown.
Phosphotidylserine (PS), phosphatidylcholine (PC) and phosphatidylethanolamine (PE)
predominate among phospholipids in EVs demonstrating PS exposure on the outer membrane
leaflet (32, 134, 138).
In accordance with their abundance in EV membranes, sphingolipids, cholesterol and
specific phospholipids are associated with several EV biogenesis mechanisms. Our knowledge of
the roles lipids play in EV biogenesis comes from studies on the enzymes that modify and
organize lipids in the cell. Neutral Sphingomyelinase 2 (nSMase2) was initially implicated in the
biogenesis of exosomes bearing proteolipid protein and CD63 (104), and this mechanism has
been verified for other cell types and cargos (43). nSMase2 hydrolyzes sphigomyelin to form
ceramide and phosphatidylcholine. The observation that ceramide causes small vesicles to form
within giant unilamelar vesicles provides a model for ceramide-driven MVB formation (104).
Sphingosine 1-phosphate (S1P) activates S1P receptors at endosomes and promotes MVB
formation, but details of the downstream signaling in this pathway are unknown (139).
Phospholipase D hydrolyzes phosphatidylcholine to generate choline and phosphatidic acid.
Phospholipase D2 (PLD2) is released on EVs, localizes to endosomes and regulates MVB
formation and exosome secretion (140, 141). At the plasma membrane, flippase, floppase and
scramblase enzymes use ATP hydrolysis to transfer lipids between leaflets of the bilayer and
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maintain bilayer asymmetry. In C. elegans embryos, the TAT-5 ATPase prevents extracellular
phosphatidyl ethanolamine exposure and negatively regulates ectosome budding (6). Despite
these strides toward understanding lipids in EV biogenesis, much remains to be learned about
how changes in lipid composition are localized and triggered during EV formation.
Few large-scale lipidomics studies have been reported for EVs compared to the vast
amount of proteomics data. More such analyses are needed. Careful lipid characterization could
identify less abundant species that might provide hints about EV origin. All of the lipids
mentioned above are present at both the plasma membrane and on endosomes and thus cannot
discriminate between EVs derived from these membranes. However, proportional lipid
composition is expected to differ somewhat among EV types since proteins that preferentially
bind ganglioside or phosphatidylserine concentrate EVs with different protein and RNA profiles
(142). Phosphatidylinositol (PI) levels in EVs are similar to whole cell membranes, but only a
subset of acyl chain length and saturation categories were identified in one study (134, 143). The
inositol head group of PI is phosphorylated to different degrees, and these species are generally
restricted to specific cell membranes where they are involved in trafficking regulation.
Therefore, these lipids could potentially be relevant markers distinguishing exosomes and
ectosomes.
1.3.4

Ubiquitin
Ubiquitination serves as an important sorting signal during endocytosis and MVB

formation (144). Ubiquitin interactions with the ESCRT machinery, which comprises the
primary sorting mechanism for ESCRT-dependent lysosomal degradation, are discussed in
section 1.3.1. Similar interactions function in ESCRT-dependent enveloped virus budding from
the cell surface (145). EVs contain ubiquitinated proteins, although one study found that the
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majority is soluble suggesting that if ubiquitin is important for cargo sorting then either ubiquitin
is removed from transmembrane proteins before vesicle budding or ubiquitinated soluble
proteins interact with transmembrane proteins to provide the ubiquitin signal (146, 147).
Evidence for specific roles for ubiquitination in EV biogenesis includes ARRDC1 ubiquitination
by the WWP2 E3 ligase promoting formation of ARRDC1 ectosomes (110). Mouse
macrophages release M. tuberculosis proteins in EVs in an ubiquitination-dependent manner
during infection or after exposure to secreted M. tuberculosis proteins (148). Silencing the
ubiquitin-binding ESCRT-0 protein Hrs dampened release of ubiquitinated proteins in EVs from
dendritic cells (149). Intriguingly, MHC II ubiquitination is important for lysosomal degradation
of MHC II but not for sorting it to exosomes (108, 150). However, MHC II interacts with several
other proteins in EVs (151). Some of these, such as heat shock proteins and pyruvate kinase,
were independently reported to be ubiquitinated in EVs (146). This opens the possibility that
direct ubiquitination and interaction with certain ubiquitinated proteins could be competing
mechanisms for delivering MHC II to lysosomes or exosomes. Such a hypothesis has yet to be
explored for MHC II or for other cargos. An example of ubiquitin bridging is the ESCRTdependent sorting of lumenal GPI-anchored proteins recently described in yeast. This bridging
function is carried out by the Cos proteins (152). The Cos family is comprised of 11 heavily
ubiquitinated, four-pass transmembrane proteins. It has been speculated that the unique Cos
transmembrane domains could be important for organizing lipidated cargo into membrane
domains. Computational studies suggest possible biophysical similarities between Cos and
tetraspanin transmembrane domains (153). One missing aspect to this parallel is that few studies
have reported tetraspanin ubiquitination (154). However, it is possible that this role could be
fulfilled by cytosolic tetraspanin binding proteins that are ubiquitinated or interact with
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ubiquitinated proteins. For example, the syntenin-1 PDZ adaptor protein binds to CD63, is
ubiquitinated and interacts with ubiquitinated proteins (155, 156). It will be interesting to see if
future studies identify ubiquitinated and ubiquitin interacting proteins that link functionally
relevant cargo to EV budding machinery.
1.3.5

Actin
Actin forms a dense and dynamic filament network underneath the plasma membrane to

which it is tightly coupled (157). An extensive number of proteins regulate actin dynamics
including proteins that stabilize or destabilize filaments, promote filament branching and halt
filament elongation. Actin and actin regulating proteins are likely to be important for EV
biogenesis since actin dynamics is coordinated with endocytosis and secretion (158). The actin
cortex is likely to play a direct role in ectosome budding. The Rho family GTPases govern actin
dynamics and allow the cell to rapidly change its architecture in response to environmental cues
(158). RhoA is implicated in EV release from several tumor cell lines. Constitutively active
RhoA but not Ras, Rac, Cdc42 or other Rho isoforms cause an increase in the amount of tissue
transglutaminase and flotillin-2 released on EVs (159). The major RhoA effector, Rho-associated
coiled coil-containing kinase (ROCK), is involved in this pathway through activation of LIM
kinase and subsequent phosphorylation of cofilin, which inhibits cofilin’s actin-depolymerizing
activity. These data suggest roles for regulated actin polymerization in EV release, although a
direct mechanism has yet to be characterized. There are interesting parallels between this
pathway and the pathway involved in regulation of plasma membrane blebbing (160). During
non-apoptotic blebbing, myosin-based contraction of the actin cortex initiates detachment of the
plasma membrane from the underlying cytoskeleton followed by flow of cytosol and lipids into
an expanding membrane bleb. The actin cortex eventually reassembles inside the bleb, and
myosin-based contraction causes retraction into the cell body (161). An alternative pathway
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could promote abscission at the bleb neck downstream of actin polymerization. A few aspects of
blebbing dynamics open other possibilities for EV release. Blebbing first requires an increase in
membrane surface area, which could be provided by unfolding of microvilli structures or by
exocytic vesicles (161). Exocytosis of MVBs would then give rise to exosome secretion.
Whether exocytosis accompanies blebbing remains an open question. Likewise, membrane
surface area decreases during retraction. Membrane refolding, endocytosis and ectosome
shedding could be tactics for dealing with excess membrane. Blebbing is associated with a
specific mode of cell migration particularly employed by tumor cells (162). Understanding how
this process is coupled to EV expulsion awaits future studies that will likely reveal novel aspects
of EV function.
1.3.6

MVB secretion
The ultimate step in exosome secretion is fusion of the MVB with the plasma membrane.

The proteins and lipids involved in MVB formation were discussed in previous sections. Here, I
will discuss the proteins that regulate endocytic trafficking and membrane fusion processes. An
extensive network of soluble and membrane associated proteins regulates all of membrane
trafficking. Several subclasses of the Ras family of GTPases mediate vesicle formation, transport
and fusion across many aspects of membrane trafficking. These include Rab, Arf and Ral
families, which act as molecular switches by cycling between active, GTP-bound and inactive,
GDP-bound states. Guanine nucleotide exchange factors (GEFs) promote exchange of GDP for
GTP, and GTPase activating proteins (GAPs) enhance Rab intrinsic GTPase activity. Effectors
bind activated G proteins to mediate their functions. Effectors include coat proteins that function
in vesicle formation, motor proteins that transport vesicles to their destination along
microtubules and tethering proteins that link transport and target membranes. Once vesicles are
tethered to their target membrane, SNARE proteins on both the target and transport vesicle
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(tSNAREs and vSNAREs, respectively) interact and catalyze membrane fusion. SNAREs
interact with Sec1/Munc18 (SM) proteins and tethering proteins that regulate the specificity and
fidelity of the fusion reaction. Representatives of all of the proteins discussed above are
implicated in exosome secretion.
Rab proteins—Rab5 identifies early endocytic vesicles and mediates their transport and
homotypic fusion. Overexpressing GTP-locked Rab5 promotes fusion causing enlarged
endosomes and inhibits recycling pathways (163). Not surprisingly, this mutant reduces exosome
release from different cell types (104, 106). Early endosomes mature to late endosomes as Rab7
replaces Rab5, which is required for fusion with lysosomes (164). Silencing Rab7 expression
reduces exosome secretion from MCF7 cells and causes formation of enlarged MVBs that
accumulate lumenal vesicles (106). Because both Rab5 and Rab7 are critical mediators of
endosomal flux, demonstrating that they affect exosomal cargo secretion is strong evidence
supporting involvement of the endosomal pathway in exosome biogenesis. However, because
neither Rab5 nor Rab7 seems to promote fusion with the plasma membrane, these observations
highlight the challenges in pinpointing specific roles for proteins shown to perturb exosome
release.
Early endosomes also generate recycling endosomes that return membrane and proteins
back to the plasma membrane. Rab11 is one of several Rabs that mark recycling compartments.
The human erythroleukemic cell line K562 provides an excellent system for investigating the
role of Rab11 in exosome secretion. It expresses high levels of Rab11 and therefore displays
enhanced Rab11-dependent processes (165, 166). Transferrin receptor is sorted to MVBs and
released on exosomes after stimulating K562 cells with transferrin (167). Therefore, transferrin
receptor is a marker of exosomes in this system. Overexpressing wild-type or GTP-locked Rab11
25

increases transferrin receptor exosome secretion, while overexpressing GDP-locked Rab11
decreases it (167, 166). Interestingly, a rise in intracellular calcium caused enlarged Rab11labeled MVBs to form as a result of endosome fusion (166). Rab11 localizes to late recycling
and post-golgi compartments suggesting that Rab11 may function in early steps of organelle
maturation during exosome secretion (168). Rab11 may also play a role in tethering secretory
organelles to the plasma membrane as it localizes there and interacts with the Sec15 subunit of
the exocyst complex, known to play a role in plasma membrane docking (167, 169). It is
currently not known if the Rab11-exocyst pathway generally contributes to exosome secretion.
Rab35 is also involved in recycling pathways and was shown to be involved in exosomal
secretion of proteolipid protein from oligodendroglia (170, 171). Silencing or deactivation of
Rab35 decreases exosome secretion. Overexpressing its GAPs, TBC1D10A-C, has the opposite
effect. Patch-clamp experiments revealed that overexpressing GDP-locked Rab35 reduces fusion
of vesicles with the plasma membrane (171). It is still unclear whether these fusion defects are
direct or a consequence of fewer vesicles delivered to the plasma membrane.
Rab27a and Rab27b were identified in an RNAi screen for defective exosome secretion
from HeLa cells (32). Rab27 function in secretion is well studied in several specialized cell
types. In some cells, Rab27 localizes to and regulates secretion of late endosome/lysosome
related organelles such as melanosomes, platelet dense granules and lysosomes in cytotoxic T
lymphocytes (172-175). Constitutive secretion from polarized epithelia also involves Rab27
suggesting that these small G proteins are common components in multiple secretory pathways
(176). Rab27a and Rab27b have been suggested to act at different steps in exosome secretion
through different effector proteins. Knockdown of Rab27a and its effector Slp4a knockdown
increased MVB size and decreased the number of immobile (plasma membrane-docked) MVBs
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as observed by TIRF microscopy (32). In contrast, knockdown of Rab27b or its effector Slac2b
redistributed MVBs to the perinuclear region, decreased MVB size and increased rapid
movement along microtubules. These results were interpreted to suggest that Rab27b is involved
in delivering secretory MVBs to the cell periphery while Rab27a is involved in docking to the
plasma membrane. These functions are in line with those characterized for other secretory events
since Slp4a regulates docking of secretory granules (177). Depleting Rab27a and/or Rab27b has
since been shown to affect exosome secretion in other model systems (55, 178).
Other small G-proteins—Arf GTPases act together with diverse effector proteins to
regulate trafficking in both the secretory and endocytic pathways. Of these, Arf6 has been
implicated in secretion of exosomes from MCF-7 cells, acting upstream of syntenin-1 (141). This
function involves at least one GEF protein, ARNO, and PLD2. Interestingly, depleting Arf6 also
interferes with EGFR degradation demonstrating a broad function in MVB biogenesis. It is
possible that Arf6 and PLD2 act upstream of a sorting mechanism that traffics MVB membranes
away from the degradative pathway.
The Ral family of GTPases is comprised of two proteins, RalA and RalB, which function
in secretion of platelet dense granules, Weibel-Palade bodies and cytotoxic T lymphocyte
lysosomes (179). A Ral homologue in C. elegans, Ral-1, is involved in MVB formation since
ral-1 gene deletion alters MVB morphology and reduces the number of lumenal vesicles (180).
Silencing RalA or RalB expression in mouse 4T1 cells impairs secretion of several exosome
markers indicating that Ral function in MVB biogenesis and exosome secretion extends to
mammals. In contrast to gene knockout, decreasing Ral-1 levels with RNAi causes an increase in
the number of MVBs in close proximity to the plasma membrane leading to the interpretation
that Ral-1 acts on both MVB formation and fusion with the plasma membrane (180). The major
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Ral effector protein in many secretion processes is the Sec5 subunit of the exocyst complex
(179). Potential involvement of the exocyst in exosome secretion has yet to be directly tested.
Interestingly, oncogenic Ras activates Ral proteins providing a possible explanation for increased
exosome secretion by tumor cells (179).
SNAREs—VAMP7 is a SNARE protein involved in fusion of vesicles derived from Golgi
and late endosomes with the plasma membrane (181, 182). VAMP7 is localized to endosomes
through interaction with Varp, a Rab32 GEF. Varp directly interacts with the VPS29 subunit of
the retromer complex linking it and VAMP7 to late endosome trafficking to the plasma
membrane (182). Inhibition of VAMP7 by overexpressing its inhibitory longin domain causes
enlarged MVBs decorated with both Rab11 and VAMP7 to accumulate close to the plasma
membrane suggesting a defect in plasma membrane fusion (183). Accordingly, exosome
secretion from K562 cells is dampened by VAMP7 inhibition.
Ykt6 is a SNARE protein best characterized for its functions at the ER and Golgi. In
addition, this SNARE functions in endosome to Golgi trafficking (184, 185). Depleting Ykt6
causes accumulation of CD63 and Wnt in D. melanogaster and human cells and decreases
secretion of these proteins on exosomes from human cells (8). Interestingly, Ykt6 depletion did
not affect delivery of transmembrane proteins to the cell surface arguing against effects on the
general secretory pathway, which would deprive the endocytic pathway of cargo. These data
suggest that sorting and flux from the MVB to Golgi is important for maintaining MVB
homeostasis.
Calcium—As mentioned above, a rise in intracellular calcium triggers exosome secretion
in several systems (149, 171, 186-188). Responsivity to calcium is a common feature of many
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secretory processes. This is most extensively characterized for synaptic vesicle secretion from
neurons. In these cells, vesicles are delivered and docked to the plasma membrane where
SNARE complexes become primed or locked prior to a localized increase in calcium that
triggers fusion. Synaptotagmins interact with SNARE proteins and constitute the primary
calcium sensors for rapid calcium-evoked release (189). To date, no synaptotagmin protein has
been directly implicated in exosome release. Synaptotagmin-VII mediates the calcium-dependent
fusion of lysosomes with the plasma membrane in cytotoxic T lymphocytes, fibroblasts,
osteoclasts and during plasma membrane repair (190-193). VAMP7, the only SNARE thus far
implicated in fusion of secretory MVBs with the plasma membrane, forms complexes with
synaptotagmin-VII during calcium-dependent lysosome exocytosis (194). It remains to be seen if
synaptotagmin-VII functions extend to other endosomal compartments including MVBs.
Secretion of platelet dense granules is also triggered by increased cytosolic calcium. Rab27 and
its calcium-binding effector Munc13-4 in concert with Ral proteins and the exocyst complex
mediate this process (175, 179, 195). Recently, Munc13-4 was shown to interact with Rab11 to
mediate docking of vesicles at the plasma membrane (196). While calcium is clearly involved in
different types of exosome secretion, we know very little about the kinetics of this process.
Sensitive real-time assays of exosome secretion will be required to understand this response to
calcium. Such studies could reveal whether different cell types produce readily releasable pools
of MVBs similar to those of synaptic vesicles.

1.4

Aims of the thesis
Develop and optimize methods for monitoring EV release from cultured cell lines—Tools

for polymer-based precipitation of EVs have been developed commercially as well as in
independent laboratories to concentrate EVs from a variety of source fluids. Commercial kits
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utilize a proprietary synthetic polymer at a defined salt concentration to “cage” EVs and promote
precipitation (197). Polyethylene glycol (PEG) precipitates EVs by a comparable mechanism.
PEG is hygroscopic and thus shields EVs from water molecules causing them to fall out of
solution. The precipitated material is then pelleted by relatively low centrifugal force. Polymerbased precipitation is not a selective method; therefore, it is best suited for broad analysis of EV
populations. Most studies of EVs use inefficient, low throughput methodologies to collect
vesicles. Furthermore, because of the typically slow but still poorly characterized rate at which
EVs are released, most studies analyze EVs collected over extended (hrs to days) time periods.
To screen for changes in EVs using small sample volumes (~1 ml culture media) as well as over
short (≥1hr) time frames, I developed a particle concentration protocol using polyethylene glycol
(MW 3350) precipitation followed by binding to ConA sepharose, washing, and elution with aD-methylmannoside, based on earlier studies of viruses (198, 199). I refer to this protocol as
PEG/ConA EV isolation and found it to be comparable to standard EV collection procedures in
its relative recovery of typical EV components. Since EVs could be collected from culture
medium exposed to cells for short times, I was able to assess the effects of brief pharmacological
treatments on EV release. The PEG/ConA procedure therefore became a key resource during the
course of my thesis work.
Test the role of VPS4 and ESCRT-III in EV biogenesis—The idea that ESCRT machinery
and VPS4 might be involved in EV biogenesis is not new, but a clear understanding of exactly
how and when they participate has remained elusive. Reports of ESCRT-independent ILV
formation, exosome biogenesis, and microvesicle shedding have led to a working consensus that
there must be other ways of controlling these events in mammalian cells. For ILV and exosome
formation proposed alternate models center on the involvement of particular lipids and lipid raft-
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like domains, while microvesicle release is attributed to the activity of cytoskeletal machinery.
While it is certainly clear that lipid- and protein-based segregation into budding-prone domains
must be a part of the ILV and EV-forming process, many of the experiments testing involvement
of the ESCRT machinery have focused on components of the initiating ESCRT-0 or –I
complexes (104, 110, 200) with only a few attempts to assess involvement of ESCRT-III and
Vps4 (29, 106, 111). In the case of ESCRT-III, the fact that filaments assemble from a mixture
of as many as 12 subunits (some of which may be functionally redundant while others might
have other functions altogether) complicate interpretation of gene depletion experiments.
Removing a single ESCRT-III protein as in a widely cited study of ESCRT function in
multivesicular endosome biogenesis (201) does not address the overall contribution of ESCRTIII to pathway function. Therefore, I globally blocked ESCRT-III polymer disassembly by
expressing a dominant negative mutant of VPS4 (VPS4EQ). Inducibly expressing VPS4EQ
caused a marked decrease in release of canonical EV tetraspanins, CD63 and CD9. Furthermore,
VPS4 inhibition changed the protein profile of EVs residually secreted from cells. Notably, the
concentration of ESCRT-III subunits in EVs was elevated despite a clear reduction in the number
of EVs. These findings implicate VPS4 and ESCRT-III disassembly in the biogenesis of
different EV types.
Characterize EV heterogeneity based on differential protein content—CD63 and CD9 are
among the most abundant and frequently identified proteins on EVs (16, 202). CD63 is
primarily localized to membranes inside of MVBs while CD9 and most other tetraspanins reside
primarily on the cell surface (203). Specific functions for individual tetraspanins have been
difficult to pinpoint, but all function as membrane protein scaffolds and mediate important
interactions with integrins, kinases, and other cell surface receptors (203). Both CD63 and CD9
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have been implicated in formation of specific EVs (54, 105) but neither has emerged as a
universally required factor, and overexpression has not been shown to significantly change EV
release. CD9 is implicated in processes such as proliferation, migration and cell surface
contraction (204). Work described in this thesis and from others suggests that release of these
proteins onto EVs may be separable (22, 23, 205). Immunostaining reveals different distributions
for both endogenous and overexpressed proteins in cells. I demonstrate, using continuous sucrose
density floatation, that CD63 and CD9 are enriched on physically separate EV populations. I also
find that serum is a robust stimulator of EV release from the cell surface. In order to more deeply
investigate the extent to which these proteins segregate on different EVs, I developed cell lines
expressing different combinations of fluorescent tetraspanin fusion proteins. This work paves the
way for sensitive assessment of EV heterogeneity based on CD63 and CD9 as putative markers
of exosomes and ectosomes, respectively.
Investigate the exocytic MVB—With specific regard to exosome release, an important
question is what distinguishes MVBs destined for exocytosis from those destined for
degradation. Currently, the most well characterized factors involved in the actual trafficking and
release of exocytic MVBs are Rab27a and Rab27b. I have identified Rab27b as a factor likely to
distinguish exocytic from non-exocytic MVBs in U87 cells. Rab27b localizes to a subset of late
endosomes that also contain the exosomal protein CD63. I found that this subset of MVBs are
less acidic than remaining (Rab27b negative) MVBs. Furthermore, endosome pH appears to play
a direct role in recruiting Rab27b since chloroquine neutralization increases both Rab27b
endosomes and CD63 release. These findings have exciting implications regarding the identity of
MVBs and how their exocytosis is regulated.
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FIGURE1-1. Cells release different types of extracellular vesicles. A, Schematic of the different membranes from which EVs arise. B, EM image of a MVB containing immunogold-labeled transferrin fusing
with the plasma membrane to release transferrin receptor-bearing exosomes. Scale bar = 200nm.2 C, EM
image of ectosome release. Arrows show sites of budding from the plasma membrane (PM) of breast
cancer cells. Scale bar = 500nm.3
2 Harding, C., P. Stahl. 1983. Transferrin recycling in reticulocytes: pH and iron are important determinants of ligand

binding and processing. Biochem. Biophys. Res. Commun. 113:650–658.
3 LoCicero, A., P. Stahl, G. Raposo. 2015. Extracellular vesicles shuffling intercellular messages: for good or for bad.
Curr Opin Cell Biol 35: 69-77.
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Chapter 2
Inhibiting VPS4 impairs extracellular vesicle
biogenesis and demonstrates a broad role for
ESCRTs in exosome and ectosome release
Abstract
Extracellular vesicles (EVs) play important roles in intercellular communication. Two
broad classes of EVs can be distinguished by their intracellular origin. Exosomes are generated
within endosomes and released when these fuse with the plasma membrane, while ectosomes
bud directly from the plasma membrane. Topologically equivalent processes including
intralumenal vesicle formation for degradation in the endosomal pathway and virus budding
from the plasma membrane depend on Endosomal Sorting Complex Required for Transport
(ESCRT)-III and the ATPase VPS4 for membrane fission and release. Whether this machinery is
generally required for EV biogenesis has, however, been the subject of debate. Here, we use two
complementary methods for isolating EVs from cultured cells and demonstrate that inhibiting
VPS4 stabilizes ESCRT-III polymers and correspondingly reduces constitutive release of both
protein and miRNA in EVs. Notably, we find that tetraspanins that preferentially reside on
different membranes are enriched on distinct populations of EVs, both of which depend on VPS4
activity for their release. Stimulating cells with serum increases EV release primarily from the
plasma membrane and is again VPS4-dependent. All together, our data indicate that inhibiting
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VPS4 blocks both exosome and ectosome release thereby generally implicating ESCRT-III in
EV biogenesis.

Introduction
Extracellular vesicles (EVs) are released by virtually all cells and are present both in
tissues and in a variety of body fluids (1). Early observations revealed roles for EVs in
discarding membrane proteins during reticulocyte maturation (2, 3) and in eliciting immune
responses (4, 5). Since then it has become clear that EVs modulate cell behavior in numerous
ways and function broadly in intercellular communication (6). EVs can be classified based on
their tissue of origin, e.g. prostasomes derive from prostate cells, oncosomes from tumor cells,
etc. However, each cell can also release EVs from different membranes. Exosomes are released
when endosomal multivesicular bodies (MVBs) fuse with the plasma membrane (7). Ectosomes
or shedding microvesicles are released directly from the plasma membrane (8, 9). Differentiating
among these by standard techniques is difficult, and it is likely that most EV preparations include
both types of vesicles (10, 11).
EVs contain proteins, lipids, and RNA. If EVs indeed represent specific signaling entities
then mechanisms are needed to selectively package cargo molecules into them. Our
understanding of this sorting is still incomplete, but numerous molecules are known to be
overrepresented in EVs. These include the widely expressed tetraspanins CD63, CD81, and CD9.
Tetraspanins are four-pass transmembrane glycoproteins known for their propensity to assemble
into tetraspanin enriched microdomains (12) that may play roles in defining EV content.
Exosomes from CD81 deficient T lymphocytes are selectively missing proteins that interact with
CD81 (13). CD9 directs release of the membrane endopeptidase CD10 on EVs (14). CD63
interacts with premelanosomal protein and mediates its sorting to ILVs released from
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melanocytes (15). Similar proteins in yeast have recently been identified as organizers of nonubiquitinated MVB cargo (16). Other proteins frequently detected in EVs include adaptor-type
molecules such as ALIX and syntenin-1 that may help to recruit soluble cargo (17). A few
factors specifically implicated in concentrating RNA in EVs include sumoylated heterogeneous
nuclear ribonuclear protein A2B1 (18) and annexin a2 (19), Overall, however, much remains to
be understood about mechanisms responsible for sorting specific cargo to EVs.
In addition to selecting cargo, producing EVs requires machinery to deform the
membrane and release vesicles. Polymers of ESCRT-III drive membrane fission in topologically
comparable events including virus budding and intralumenal vesicle formation, acting as spiral
coils to constrict vesicle necks (20, 21). The AAA+ ATPase VPS4 remodels and disassembles
ESCRT-III filaments, and is essential for ongoing ESCRT-III function. Because of these roles,
ESCRT-III and VPS4 have long been considered likely to play central roles in EV biogenesis.
However, specific attempts to test their involvement have provided contradictory results. These
contradictions may result at least in part from the modularity of the ESCRT machinery. If
ESCRT-III function is indeed generally employed for EV membrane fission, we expect
inhibiting it to have a general effect on EV release. Here we use stable cell lines in which
expression of an inhibitory VPS4 mutant is tightly regulated and inducible to test the effects of
uniformly inhibiting ESCRT-III remodeling on EV release. We also develop and characterize an
efficient, small-scale method for collecting EVs. Our results demonstrate that inhibiting VPS4
blocks both exosome and ectosome release thereby generally implicating ESCRT-III in EV
biogenesis.
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Methods
Antibodies, Plasmids and reagents—Antibodies used include mouse monoclonal
antibodies against CD63 (Dev Biostudies (H5C6) or Ancell (46-4-5)), CD9 (Serotec
MCA496GA), mCherry (Novus Biologicals (96752)) and rabbit polycolonal antibodies against
CHMP4A (22), calnexin (Cell Signaling Technologies (2433)), and syntenin-1 (ProteinTech
(22399)). Secondary antibodies were conjugated to horseradish peroxidase for immunoblotting
(ThermoFisher), IRdye800CW for infrared-based cell quantitation (LiCor) and Alexa Fluor 488
immunofluorescence (ThermoFisher).
pEGFP-CD63 (kind gift from Paul Roche, NIH) was used to generate pmCherry-CD63
using BamHI and XhoI sites. GFP-CD9 was generated by transferring CD9 from pcDNA3.1
FLAG-CD9 (kind gift from Michael Caplan, Yale School of Medicine) into pEGFP-C2 between
BamHI and XhoI sites. GPI-mCherry was a kind gift from Gerald Baron (Rocky Mountain
Laboratories, NIAID, NIH).
HEK293TREx cells with tetracycline inducible VPS4AE228Q or VPS4BE235Q described in
(22, 23) were maintained in 5µg/ml blasticidin and 100µg/ml zeocin. PANC-1 cells were from
ATCC. U87 cells were from Joshua Rubin (Washington University School of Medicine). All cell
lines were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10%
tetracycline-tested fetal bovine serum and 1mM L-Glutamine. Cell lines stably expressing the
indicated exogenous constructs were generated by transfecting with Lipofectamine 2000
(Invitrogen) followed by selection with 500µg/ml G418.
Chemicals were from Sigma Aldrich (St. Louis, MO) unless otherwise noted. Protein
concentrations were determined with Bio-Rad protein assay reagent using bovine serum albumin
as a standard.
69

EV collection by differential centrifugation—EVs were collected into culture medium
containing fetal bovine serum depleted of exosomes by overnight centrifugation at 100,000 × g.
To concentrate EVs, EV containing medium was cleared of larger membranes by spinning at
1,500 × g for 10 min followed by 10,000 × g for 30 min or passage through a 0.2µm PVDF low
protein binding syringe filter (Millipore). EVs were then pelleted from this supernatant at
100,000 × g for 2 hr, resuspended in 1ml phosphate buffered saline (PBS), and pelleted again at
100,000 × g for 1 hr. Unless otherwise indicated in figure legend, final EV pellets were
suspended in PBS in a volume normalized to the total protein content of the cells from which
they were derived and used for immunoblotting.
Sucrose gradients—EV pellets obtained by differential centrifugation were suspended in
2 ml of 20 mM HEPES pH7.4, 2.5 M sucrose and placed in the bottom of a SW41 centrifuge
tube. A 10ml linear sucrose gradient (2M-0.25M sucrose, 20mM HEPES pH7.4) was layered
over this and then centrifuged at 210,000 × g for ≥14 hr. 1ml fractions were collected, diluted
with 3ml TBS (20mM Tris pH7.5, 100mM NaCl) and bound to nitrocellulose by passage through
a slot blot apparatus (Minifold I (Midwest Scientific)). The membrane was dried and subjected to
immunoblotting for EV proteins.
EV collection by polyethylene glycol precipitation and concanavalin A binding—Culture
media was cleared of larger membranes as described for differential centrifugation and then
combined with an equal volume of 40% polyethylene glycol (PEG, 3350 average molecular
weight) in PBS. After 1 hr on ice, precipitates were pelleted at 17,000 × g for 20 min and
resuspended in ConA binding buffer (20mM Tris-Cl pH7.4, 150mM NaCl, 2mM MnCl2, 2mM
CaCl2). Samples were incubated overnight with conconavalinA sepharose (GE Healthcare).
Beads were washed and either boiled in SDS-PAGE sample buffer or eluted with 1M α-D70

methylmannoside in binding buffer. All EV isolates were normalized to the total protein present
in the cell cultures from which they were isolated.
SDS-PAGE and immunoblotting—Samples were boiled in SDS-PAGE sample buffer
(2% SDS, 60mM Tris pH 6.8, 0.01% bromophenol blue, 10% glycerol) with or without 1% βmercaptoethanol for 5 min and spun for 2 min at 21,000 × g. CD63 and CD9 immunoblotting
required non-reducing conditions. Proteins were separated on 10% gels followed by transfer to
nitrocellulose. Membranes were blocked and probed in TBS, 0.05% Tween and 5% nonfat dry
milk. Blots were imaged on a ChemiDoc MP imaging system (Bio-Rad) and quantitated with
Bio-Rad Image Studio software.
Quantitative RT-PCR analysis of miRNA—EVs collected by differential centrifugation
were suspended in PBS and RNA was isolated using TRIzol LS (Invitrogen). Samples were
spiked with 100nM C. elegans synthetic miRNA as a control (cel-miR-39, 5’UCACCGGGUGUAAACAGCUUG-3’). cDNA synthesis was primed with hairpin stem-loop
oligonucleotides as previously described (24) (miR-92a, 5’GCGTGGTCCCGACCACCACAGCCGCCACGACCACGCACAGGC-3’; miR-150, 5’GCGTGGTCCCGACCACCACAGCCGCCACGACCACGCCACTGG-3’; cel-miR-39, 5’GCGTGGTCCCGACCACCACAGCCGCCACGACCACGCCAAGCT-3’). cDNA was
amplified in an ABI Prism 7500 Fast real-time PCR machine for 40 PCR cycles using SYBR
green PCR master mixture (Applied Biosystems), 100 nM template specific (miR-92a, 5’GTGACGATCTATTGCACTTGTCCCG-3’; miR-150, 5’GTGACGATCTCTCCCAACCCTTGTA-3’; cel-miR-39, 5’CAGTGACGATCTCACCGGGTGTAAATC-3’), and a 100 nM universal reverse primer (5’-
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TCCCGACCACCACAGCC-3’). Relative quantification of miRNA expression was performed
using the comparative threshold method with normalization to cel-miR-39.
Fluorescent EV particle counts—EVs collected by differential centrifugation were
resuspended in PBS in a volume normalized to the total protein content of the cells from which
they were collected. 1µl was placed on a glass slide, overlaid with a 12 mm diameter glass
coverslip pre-coated with poly-L-lysine, and imaged by widefield fluorescence microscopy as
described below. Counting of thresholded images was done using the particle counting plug-in in
ImageJ.
Immunofluorescence—Cells on poly-L-lysine coated #1.5 glass were fixed in 2%
paraformaldehyde in PBS, permeabilized with 0.1% saponin, and blocked and stained with
antibodies diluted in PBS containing 5% goat serum and 0.01% saponin.
Microscopy—Imaging was performed with an Olympus IX81 microscope equipped with
a 60×/1.42 NA oil objective. Confocal images were obtained with a Yokogawa CSU-10 spinning
disc confocal and a Cascade 512B camera. Widefield images for particle counting were acquired
with a Hamamatsu Flash 2.8 camera.
Infrared (IR) immune-labeling and quantitation—Cells plated in poly-L-Lysine coated
24-well plates at varying densities were fixed and stained as for immunofluorescence using
IRdye secondary antibodies. Staining was detected on an Odyssey infrared imager (Li-Cor).

Results
CD63 and CD9 reside on separable populations of EVs—The tetraspanins CD63 and
CD9 are among the proteins most commonly recovered in EVs (25). Interestingly, these two
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proteins do not typically share the same subcellular distribution: CD63 is enriched on
intralumenal vesicles within MVBs (26) while CD9 localizes primarily to the plasma membrane
(27). We confirmed this contrasting localization in HEK293 cells stably co-expressing mCherryCD63 and GFP-CD9 (Figure 1A). Quantitative comparison of surface and total tetraspanin
immunostaining revealed a similar distribution for the endogenous proteins in untransfected
HEK293 cells (Figure 1, B and C).
Based on their differential localization, we wondered if CD63 and CD9 might be
enriched in distinct EVs that separately derive from their primary membrane of occupancy, the
MVB and the plasma membrane. To assess this, we isolated EVs by differential centrifugation
using a typical protocol (28, 29) (Figure 1D). We refer to the resulting EV pellet as the “100k EV
fraction.” As a general rule, we attempted to maintain comparable culture conditions across all
EV collection experiments (e.g. cell density and time in culture before beginning EV collection)
to avoid significant losses and variation due to elusive factors such as EV adherence to culture
dishes or re-uptake by cells. To determine how homogenous the EVs bearing CD63 and CD9
are, we floated the 100k EV pellet to equilibrium in linear sucrose gradients (Figure 1D).
Immunoblot quantitation demonstrated that membranes containing CD63 peak at 1.13 g/ml
(Figure 1E). This is similar to the previously reported density of exosomes (4, 26). In contrast,
membranes containing CD9 were most concentrated at 1.2-1.24 g/ml. These results indicate that
CD63 and CD9 are differentially enriched on separable extracellular membranes, potentially
corresponding to exosomes and ectosomes.
Collecting EVs by polyethylene glycol precipitation and binding to concanavalin A—
Isolating EVs by ultracentrifugation requires large numbers of cells and long collection times to
obtain a manageable pellet. This limits the resolution of experiments designed to study EV
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release. We therefore developed an enrichment protocol to improve sample handling when
collecting EVs from fewer cells and/or after shorter incubations (Figure 2A). Polyethylene glycol
(PEG) has been used for decades to concentrate viral particles (30-32). Based on its hygroscopic
properties, PEG displaces water from solutes and causes them to precipitate. Since viruses and
EVs are similar in size, we used PEG to precipitate EVs from culture media. Among PEG
formulations, and in line with virus precipitation protocols, we found that 6000g/mol and
3350g/mol PEG polymers consistently precipitated the most EV-associated tetraspanin proteins.
To compare PEG precipitated EVs with those 100k EVs we repeated our sucrose gradient
analysis on PEG precipitated EV pellets. CD63 membranes peaked at 1.16 g/ml, and CD9
membranes at 1.25 g/ml demonstrating that both methods yield comparably separable EV
membranes. Serum protein coprecipitation with the EVs was lowest with 3350g/mol PEG (data
not shown). However even in pellets induced by 3350g/mol PEG we found that serum proteins –
particularly serum albumin – interfered with immunoblots when the amount of EVs was limiting,
i.e. after short collection times. To further enrich for EVs, we took advantage of the fact that
glycoproteins on the EV surface specifically bind lectins while albumin, which is not
glycosylated, does not (33). EVs contain high mannose glycans (34, 35), and we found that
conconavalin A (ConA) sepharose bound the majority of both CD63 and CD9 present in PEG
precipitates (Figure 2B). Importantly, albumin did not bind. EVs were eluted with methyl-alphaD-mannopyranoside, which binds with high affinity to ConA (36), confirming that EV glycans
were specifically bound to ConA. Using this two-step protocol of PEG precipitation followed by
ConA enrichment, we were able to reduce the number of cells and the collection times necessary
to detect CD63 and CD9 by immunoblotting.
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To compare the material recovered using this protocol (PEG/ConA) to that isolated by
differential centrifugation, we prepared EVs using each of the two methods in parallel. We
compared EVs from two cancer cell lines (PANC1 and U87) expected to release high numbers of
EVs (37) as well as from HEK293 cells. Culture media collected after 24 hr on cells was split
and EVs isolated using PEG/ConA collection or traditional differential centrifugation (Figure
2C). Immunoblotting showed that both methods produced the same relative recovery of exosome
associated tetraspanins (Figure 2C). Both methods also revealed enrichment of syntenin-1 – a
cytoplasmic adaptor protein that binds CD63 and is implicated in EV biogenesis – in EVs (17,
38) (Figure 2C). Interestingly, there was more variation in the amount of CD63 released by
different cell lines than in the amount of CD9. This trend was also previously noted in a
comparison of tumor cell EVs (39) and could be because CD63 and CD9 are, at least in part,
released on separable membranes (Figure 1E above).
Dominant-negative VPS4 reduces CD63 and CD9 release in EVs—Expressing ATPase
defective VPS4 inhibits ESCRT-III disassembly and has a dominant negative effect on ESCRTdependent processes by co-assembling with endogenous enzyme (22, 23, 40, 41). To ask how
this mutant affects EV production we turned to previously characterized cell lines that inducibly
express ATPase deficient VPS4A E228Q or VPS4B E235Q (22, 23). These cell lines allow for
rapid and uniform expression of the mutant VPS4, and have previously been used to resolve
controversies surrounding the role of the ESCRT machinery in viral budding events (23). We
tested cell lines expressing mutant forms of VPS4A or VPS4B and observed similar effects;
individual figures indicate the isoform used and the notation “VPS4EQ” refers to figures and
experiments that show data obtained with both isoforms. Treating cells with tetracycline for 2 hr
initiated expression of VPS4EQ, which then accumulated over the ensuing 16-24 hr of
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incubation (Figure 3A). Since VPS4EQ blocks disassembly of ESCRT-III polymers, we
monitored sedimentation of endogenous ESCRT-III proteins as a read-out of VPS4 inhibition
(22, 42). Polymerization of a representative ESCRT-III protein, CHMP4A, demonstrated that
ESCRT-III cycling was inhibited within 2 hr of initiating mutant VPS4 expression (Figure 3A).
To monitor the effect of inhibiting VPS4 on production and/or release of EVs, we added
EV collection media 2 hrs after initiating VPS4 expression and collected the media 24 hr later.
We prepared both 100k EVs and PEG/ConA EVs from these cells and assessed their protein
content by immunoblotting. We found that expressing VPS4EQ decreased the amount of both
CD63 and CD9 in EVs by ~50% or more (Figure 3, B-E). Notably, cellular levels of CD63 and
CD9 were strikingly stabilized (~2-fold increase) in VPS4EQ expressing cells. Firstly, this
observation clearly shows that the decrease in tetraspanin release on EVs was not simply due to
decreased protein levels. Secondly, this observation indicates that the increased cellular CD63
and CD9 is at least partly due to inhibition of their expulsion. Of course, decreased lysosomal
degradation is a likely contributing factor. Nonetheless, the fact that the amount of CD63 and
CD9 recovered in EVs was decreased despite their increased cellular expression strongly
supports our hypothesis that VPS4 is important for generating EVs bearing these proteins. While
ESCRT function has been connected to biogenesis of EVs containing syntenin-1, the effect of
VPS4 inhibition has been unclear. In line with the well-characterized role of VPS4 in regulating
ESCRT-III function, our inducible system clearly shows that VPS4EQ inhibits synteni-1 release
on EVs (Figure 3, C and E). Importantly, we did not detect the endoplasmic reticulum protein,
calnexin, in the 100k EV fractions confirming the absence of non-EV membranes even in
VPS4EQ expressing cells (Figure 3B). These results confirm that inhibiting VPS4 reduces
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release of EVs bearing both MVB and plasma membrane associated tetraspanins and an
associated adaptor protein.
Dominant-negative VPS4 decreases release of miRNA in EVs—We wondered how
broadly VPS4EQ expression affects the composition of the 100k EV fraction. To look at effects
on potential EV cargo, we tested for the presence of two representative miRNAs. We selected
miR150, which is released by HEK293 cells (43) and miR92a, which is important for cell
proliferation during development of both normal and tumor tissues (44). Both miRNAs have
been identified extracellularly in humans, likely in EVs (45). qRT-PCR analysis of the 100k EV
fraction revealed that less miR-92a and miR-150 was released from VPS4EQ expressing cells
than from controls (Figure 4A). This demonstrates that VPS4 activity is important for release of
physiologically important miRNA cargo.
Dominant-negative VPS4 decreases membrane particle release—Reduced release of
specific membrane proteins or EV-associated cargo does not necessarily indicate that the number
of EVs released is decreased and could instead reflect a change in cargo composition. We
therefore sought to independently measure the number of released EVs using fluorescence
microscopy-based particle counting (46). Glycophosphatidylinositol (GPI)-anchored proteins are
present in EVs (47), but lack cytoplasmic sorting determinants. We stably transfected VPS4EQ
inducible HEK293 cells with a plasmid encoding GPI-anchored mCherry, and confirmed that
GPI-mCherry was present at both the cell surface and on internal membranes (Figure 4B). We
therefore reasoned that GPI-mCherry is likely to be present in both exosomes and ectosomes. We
collected and prepared 100k EVs from these cells. As expected, expressing VPS4EQ reduced the
amount of GPI-mCherry detected by immunoblotting 100k EV fractions (Figure 4, C and D). In
order to count EVs, we resuspended 100k EV pellets in a defined volume, spotted them onto
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poly-lysine coated glass and counted discrete particles by widefield fluorescence microscopy.
Expressing VPS4EQ decreased the number of particles released by ~5-fold, supporting the idea
that VPS4 function is important in the overall release of EVs from the cell (Figure 4E).
Serum triggers VPS4-dependent CD9 and CD63 release—EV production is increasingly
thought to be a physiological response enabling intercellular communication. Stimuli such as
calcium ionophores and phorbol esters, which mimic and exaggerate specific effects of receptor
activation, robustly increase EV release (48, 49). In more physiologic settings, growth factors
enhance release of EVs that promote endothelial cell proliferation (50), or tumor cell migration
(51). To assess physiologically triggered EV release and determine whether it too requires
ESCRT function, we starved and then stimulated cells with serum and monitored EV release
over the ensuing 4-5 hr. Immunoblot analysis of EVs collected during this time revealed that
serum increased release of both CD63 and CD9. Interestingly, CD9 release was typically a fold
greater than CD63 release (Figure 5, A and B). For insight into the time course of this response
we analyzed EVs collected at 1 hr intervals after adding serum. Most CD63 and CD9 was
released during the first hr, demonstrating that serum triggered a rapid and transient increase in
EV release (Figure 5C). To test whether serum-stimulated EV release depended on VPS4 activity
we induced expression of VPS4EQ 4 hr prior to serum stimulation and EV collection, as above.
Immunoblotting demonstrated that VPS4EQ decreased the serum-triggered release of CD63 and
CD9 to ~25% of controls (Figure 5, D and E). These results demonstrate that serum-triggered
EV release also depends on VPS4 function and by extension on normal cycling of ESCRT-III.
Release of CD63 but not CD9 is reduced by depolymerizing microtubules—Growth
factors such as epidermal growth factor are known to stimulate release of bleb-like plasma
membrane bulges as EVs (52, 53). MVB exocytosis and exosome release is, however, also
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triggered by activating PKC or elevating calcium (54, 55). EVs recovered after serum
stimulation could therefore derive from either MVBs or the plasma membrane. We wondered
where the VPS4-sensitive EVs released after serum stimulation originate. Endosome trafficking
to the plasma membrane for exocytosis requires transport along microtubules (56), and we
therefore asked how depolymerizing microtubules with nocodazole affects CD63 and CD9
release. We reasoned that perturbing MVB trafficking would not affect ectosome release while
exosome release should be blocked. Cells were treated with nocodazole for 30 minutes prior to
EV collection. Immunostaining cells for α-tubulin clearly show that microtubules were
depolymerized after 30 minutes of nocodazole treatment (Figure 7, A and B). When these cells
were stimulated with serum, the amount of CD63 released was reduced by ~60% (Figure 7, C
and D). Consistent with the idea that CD9 EVs originate primarily at the plasma membrane, CD9
release was largely unchanged (Figure 7, C and D).
CD63 retargeted to the plasma membrane is released comparably to CD9 in EVs—While
the majority of CD63 resides on intracellular membranes, a proportion is present together with
CD9 at the plasma membrane (Figure 1B). We noticed that the amount of CD63 still released
after nocodazole treatment correlated with the proportion of CD63 normally detected at the
plasma membrane (~40%). We therefore wondered if CD63 on the plasma membrane is, like
CD9, released directly in EVs. To further explore this question, we asked how relocalizing CD63
from endosomes to the plasma membrane affects its release on EVs. Subsets of tetraspanins,
including CD63 but not CD9, possess a C-terminal YXXΦ motif important for targeting to late
endosomes and/or lysosomes via an interaction with clathrin adaptor protein complexes (57). We
stably transfected HEK293 cells with inducible VPS4AEQ with plasmids encoding mCherry
fusions of wild-type CD63 or CD63 Y236A (CD63YA). As expected (58), mCherry-CD63YA
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was visibly redistributed onto the plasma membrane compared to wild-type CD63 (Figure 7, A
and B). Quantitative immunocytochemistry revealed that the distribution of CD63YA between
the plasma membrane and internal membranes was comparable to that of CD9 (Figure 7, C and
D).
Stimulating cells expressing mCherry-CD63 with serum approximately doubled the
amount of CD63 released (Figure 7, E and F), as seen above for endogenous CD63 (Figure 5B).
Stimulating cells expressing mCherry-CD63YA with serum increased the amount of CD63
released by almost 10-fold (Figure 7, E and F). Given that the only difference between wild-type
and mutant CD63 is subcellular localization, these results support the idea that stimulating cells
with serum preferentially releases tetraspanin-containing EVs from the plasma membrane.
Importantly, we found that expressing VPSEQ reduced mCherry-CD63YA release (Figure 7, G
and H) to a similar extent as seen with CD9, further confirming a role for VPS4 and its substrates
in the release of EVs from the plasma membrane.

Discussion
Cells release a variety of EVs that differ in cargo composition, membrane of origin, and
function. This heterogeneity has complicated investigations of the mechanisms responsible for
EV biogenesis. The ESCRT machinery is frequently suggested to play an important role in this
process based both on topology and on the consistent recovery of ESCRT and ESCRT-associated
proteins in EVs. Specific roles for ESCRTs in the formation of EVs have, however, remained
unclear as different systems suggest different requirements/involvement of ESCRT and ESCRTassociated proteins. Here we provide evidence that VPS4 activity is important for the biogenesis
of two separable EV populations, implicating it and, more generally, its ESCRT-III substrates in
formation of both exosomes and ectosomes.
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VPS4 is responsible for ESCRT-III polymer disassembly, and connectivity between
VPS4 and ESCRT-III function in MVB formation, cytokinesis and virus budding is well
established (59-61). Previous attempts to characterize VPS4’s role in EV biogenesis using
dominant-negative mutant VPS4 expression have come to varying conclusions. These include
finding no effect on release of exogenously overexpressed proteolipid protein or CD63 (62) or of
endogenous CD63 (17). Other studies reveal that expressing mutant VPS4 affects release of
specific types of EVs including T-cell ectosomes (63), arrestin domain-containing protein 1
mediated microvesicles (64) and hedgehog-containing EVs – likely ectosomes – released by
epithelial cells in Drosophila melanogaster wing imaginal discs (65). RNAi based depletion of
VPS4 affects EV release in various settings albeit to varying degrees and with limited temporal
resolution (raposo, wehman, baietti). Our findings extend and generalize these previous studies
by demonstrating that acutely inhibiting VPS4 decreases release of both endosome- and plasma
membrane-derived EVs from the widely used HEK293 cultured cell line.
Expressing mutant VPS4 efficiently traps all ESCRT-III proteins in their polymerized or
filamentous state (Figure 3 and (66)), suggesting a likely role for ESCRT-III in EV production.
Only a few previous studies have addressed the contribution of ESCRT-III proteins to this
process, and have come to varying conclusions (67). The presence of 12 non-equivalent ESCRTIII proteins in humans complicates this type of analysis (68). Definitive experiments await a
better understanding of which are actually involved in different ESCRT-dependent cellular
processes.
In order to assess the generality of VPS4 function in EV biogenesis we studied two
tetraspanins, CD63 and CD9, and found that their subcellular distribution is completely different
and that they are generally released on exosomes and ectosomes, respectively. Earlier studies of
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these two “exosome markers” are, in fact, consistent with our observations. Release of CD63, but
not CD9, depends on Rab27 (10, 69). Interestingly, treating cells with heparinase selectively
stimulated CD63 but not CD9 release indicating mechanistic differences in their release (70).
Importantly, however, our finding that inhibiting VPS4 impairs release of both CD63 and CD9
implicates ESCRT-III in both exosome and ectosome biogenesis. In the future, separating these
vesicle populations will be an important step toward characterizing the specific requirements for
ESCRT proteins in each type of release.
An important aspect of this study was the development of a facile method for
concentrating EVs in a form amenable for subsequent immunoblot analysis. Our direct
comparison to traditional differential centrifugation showed that comparable EV profiles were
obtained. Despite these similarities, we cannot rule out some loss of EVs during PEG
precipitation or affinity binding. Several approaches for collecting and measuring EVs outside of
ultracentrifugation have been characterized, and each has associated benefits and caveats. Both
antibody-based immobilization coupled with fluorescence activated cell scanning and
microfluidics approaches provide sensitive detection (69, 71), but these methods are biased
toward EVs expressing specific surface antigens. Polymer based methods have been described in
the literature and are also commercially available (e.g. ExoQuick®, System Biosciences) (72,
73). These methods non-selectively collect all EVs, but method characterization has focused on
biofluids with high EV content (e.g. serum or culture medium on cells over days) and not been
used for quantitative analyses of EV release from cultured cells amenable to genetic and/or
pharmacologic manipulation. Our method of separating EVs from other precipitated protein
using lectin affinity facilitated detection of EVs released over relatively short time periods,
which is beneficial to assessing transient changes in EV release and the effects of brief
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pharmacological treatments. Given these features, we think this assay will have broad
applicability in the study of EV biogenesis.
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FIGURE 2-1. CD63 and CD9 are released on distinct EVs. A, Confocal z-stacks in orthogonal view of
HEK293 cells stably transfected with constructs expressing GFP-CD9 and mCherry-CD63. Scale bar =
10µm. B, C Untransfected HEK293 cells were immunolabeled for endogenous CD63 (B) or CD9 (C) in
the absence or presence of detergent to measure surface and total protein, respectively. Fluorescence
inside the cell or at the cell surface is shown as percent of total fluorescence. The values are mean and
standard deviation of three independent experiments. D, Flow chart of EV isolation and sucrose flotation
procedures. E, 100k EVs from HEK293 cells were floated in linear sucrose gradients. The x-axis indicates
the density of each fraction as determined by refractometry. Fractions were immunoblotted for CD63
(black line) and CD9 (gray line), quantitated and the values plotted as percent of total signal from all
fractions combined. Data show a representative experiment out of four biological replicates.
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with PEG and bound to ConA sepharose for 2hr or overnight. EV protein was released from the beads by
boiling in SDS-PAGE loading buffer. C, EVs released by the indicated cell lines over 24hr were harvested
from culture media by PEG/ConA (PEG/ConA EV) using 1/5th of the total culture supernatant or by
ultracentrifugation (100k EV) using the remaining culture supernatant. EVs released by 10% of the total
cell culture were separated by SDS-PAGE then immunoblotted for CD63, CD9 and syntenin. Cell lysates
were prepared by solubilizing in 1% Triton X-100, and 10µg of whole cell protein from each cell type was
loaded. All lanes of an indicated protein are from the same gel. Gel slicing removed an irrelevant lane.
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Figure 2-3. CD63 and CD9 EVs depend on VPS4. A, Immunoblot of whole cell protein (top panel) at the
indicated time points after induction of GFP-VPS4EQ with 0.5µg/ml tetracycline for 2 hr. Middle and
bottom panels, immunoblot of soluble supernatants and insoluble pellets separated by centrifugation at
17,000 × g. Pellets were resuspended in the same volume as supernatants, and equal volumes of each were
loaded. B, Total cellular protein from 0.05 × 106 cells (Cell Lysate) and 100k EVs from 10 × 106 cells
(100k EV) were immunoblotted for CD63 and CD9. C, Immunoblot quantitation: line indicates the
average of four independent experiments and values are displayed as percent of no VPS4 overexpression.
D, EVs from VPS4EQ-expressing HEK293 cells were collected by PEG/ConA then immunoblotted for
CD63, CD9 and syntenin. Each lane in the experiment shown represents a technical replicate prepared
from 1/3rd of the total culture supernatant. E, Immunoblot quantitation: line indicates the average of three
independent experiments, and values are displayed as percent of no VPS4EQ expression. For experiments
with technical replicates the average of the three replicates was treated as a single independent experiment.
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FIGURE 2-4. VPS4-dependent release of miRNAs and membrane vesicles. A, qRT-PCR analysis of 100k
EVs from cells expressing VPS4EQ. Values were normalized to spike-in cel-miR39 RNA and are
presented as the percent of no VPS4EQ expression. B, Single confocal section of HEK293 cells stably
expressing GPI-mCherry (scale bar = 10µm). C, Immunoblot of whole cell protein (Cell Lysate) and 100k
EVs from HEK293 cells expressing GPI-mCherry. D, mCherry immunoblot quantitation of 100k EVs is
shown as percent of no VPS4EQ expression. E, GPI-mCherry particle counts. Values are average particle
counts from 5 images. Error bars indicate standard deviation. Data show one of two biological replicates.
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FIGURE 2-5. Characteristics of serum-triggered EV release. A,B, HEK293 cells were grown for 16 hr
without serum then culture medium was replaced with fresh serum-free medium (-) or medium containing
10% serum (+) for 4 hr. EVs harvested by PEG/ConA were immunoblotted for CD63 and CD9 (A) with
immunoblot quantitation (B): line indicates the average of three experiments, and values are displayed as
the percent of no serum. C, HEK293 cells were grown 16 hr without serum before incubating in fresh
serum-free medium for 1 hr. The medium was then collected and cells were incubated with fresh medium
containing 10% serum every hr for 4 hr. EVs were harvested by PEG/ConA and immunoblotted for CD63
and CD9. D, E, Serum-triggered EVs from control and VPS4EQ-expressing cells were harvested by
PEG/ConA and immunobloted for CD63 and CD9 (D) with immunoblot quantitation (E): line indicates
the average of three experiments, and values are displayed as the percent of no VPS4EQ expression.
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with 12µM nocodazole or DMSO and immunostained for α-tubulin. C, D, Serum-triggered EVs released
from nocodazole or DMSO-treated cells were harvested by PEG/ConA and immunoblotted for CD63 and
CD9 (C) with immunoblot quantitation (D): line indicates the average of three experiments, and values are
displayed as the percent of DMSO treatment.
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presence of detergent to measure surface and total protein, respectively. Fluorescence at internal or surface
localizations is shown as percent of total fluorescence. The values are mean and standard deviation of
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Chapter 3
Rab27b is a selective and pH sensitive
marker of exocytic MVBs
Abstract
With specific regard to exosome release, an important question is what distinguishes
MVBs destined for exocytosis from those destined for degradation. Currently, the bestcharacterized factors involved in the trafficking and release of exocytic MVBs are Rab27a and
Rab27b. In this chapter, I identify Rab27b as a factor likely to distinguish exocytic from nonexocytic MVBs in U87 glioblastoma cells. Rab27b localizes to a subset of CD63 containing late
endosomes or MVBs. I find that these MVBs are less acidic than CD63 containing MVBs that
lack Rab27b. Furthermore, endosome pH appears to play a direct role in recruiting Rab27b since
chloroquine neutralization strikingly increases Rab27b on endosomes. These findings have
exciting implications for understanding how MVB identity and exocytosis is regulated.

Introduction
Aside from delivery to lysosomes, MVBs can also fuse with the plasma membrane to
release their contents from the cell. MVBs thus have two potential fates: degradation or
secretion. While degradation predominates in most situations, it is not known what controls the
fate of individual MVBs. Furthermore, MVB fate may change in response to cellular or
environmental cues. There are indications that heterogeneity among MVBs may correlate with
their eventual fate; for example, lysobisphosphatidic acid (LBPA) is concentrated in ILVs
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targeted for degradation (1) but is largely absent from exosomes (2, 3). Regulated recruitment of
appropriate Rab GTPases is likely to play a key role in this decision, with recruitment of
exocytosis-enabling Rab GTPases such as Rab27a (4), Rab35 (5), or Rab11 (6) shown to
correlate with secretion. An important and unresolved question is how MVBs destined to
undergo exocytosis differ from those that feed into the degradative pathway.
Among the Rab proteins implicated in MVB exocytosis, Rab27a and Rab27b are the best
studied based on their involvement in exosome release from several cell types using numerous
cargos. Rab proteins are recruited to specific cellular compartments by GEF proteins, act in their
GTP-bound form to recruit effector proteins, and are inactivated or released by action of GAP
proteins. One GEF and two GAPs have been identified for Rab27, and neither is specific to
Rab27 alone. MADD/DENN/Rab3GEP functions as a GEF for both Rab27 and Rab3, and its
activity toward Rab27 may be important for secretion of melanosomes and platelet dense
granules (7, 8). TBC1D10A and TBC1D10B were identified as Rab27 GAPs in vitro, and are
implicated in Rab27 inactivation in pancreatic acinar cells and melanocytes (9). Rab27 effectors
fall into one of three categories based on their structural composition. Synaptotagmin-like
proteins (Slps) are characterized by an N-terminal Rab27-binding Slp-homology domain (SHD)
and C-terminal C2 domains that bind phospholipids. Slac2 proteins comprise the second group
and posses a SHD but lack C2 domains. Slac2a and Slac2b possess regions that bind to myosins
and actin. Munc13-4 is the sole member of the third category and possesses two C2 domains that
flank the Munc domain and a unique Rab27 binding region. The Rab27 effectors are thought to
function separately or in concert to regulate secretory vesicle transport, docking, and tethering to
the plasma membrane. The precise coordination of this network and the specific members
involved are likely to differ among cell types and secretory vesicles (10).
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Despite varied tissue expression and, in some cases, apparently overlapping functions
with other Rabs (e.g. Rab3) (11), Rab27 is clearly a factor recruited to different types of
organelles that share a common secretory fate. In the following chapter, we show that Rab27b is
expressed in a restricted subset of cell types. The glioblastoma U87 cell line contained distinct
Rab27b marked organelles that corresponded to a subset of CD63 containing endosomes.
Interestingly, we find that Rab27b preferentially localized to a subset of less acidic (Lysotracker
negative) CD63 containing organelles. Furthermore, neutralizing endosomal pH by incubation
with chloroquine increased recruitment of Rab27b to CD63 containing endosomes and enhanced
CD63 release from the cell. These findings reveal unique features of secretory MVBs.

Methods
Antibodies, Plasmids and reagents—Antibodies used include a mouse monoclonal
antibody against CD63 (Dev Biostudies H5C6), a polyclonal antibody against Rab27b (Synaptic
Systems 168103), a monoclonal antibody against EEA1 (BD Biosciences 610456), a monoclonal
antibody against LBPA (Echelon Biosciences 6C4), Secondary antibodies were conjugated to
Alexa Fluor 488, Alexa Fluor 555 or Alexa Fluor 647 for immunofluorescence (ThermoFisher).
U87 cells were from Joshua Rubin (Washington University School of Medicine). MCF-7
cells were from Jason Weber (Washington University School of Medicine). Both cell lines were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum
and 1mM L-Glutamine. Lyso Tracker Red was from Invitrogen (L7528). Chloroquine was from
Sigma-Aldrich (St. Louis, MO), and 50mM (100×) stock solution was made in PBS.

105

Immunofluorescence—Cells on #1.5 glass were fixed in 2% paraformaldehyde in PBS,
permeabilized with 0.1% saponin, and blocked and stained with antibodies diluted in PBS
containing 5% goat serum and 0.01% saponin..
Microscopy—Widefield imaging was performed with an Olympus IX81 microscope
equipped with a 60×/1.42 NA oil objective and a Hamamatsu Flash 2.8 camera. Confocal
imaging was performed with a Nikon A-1 laser-scanning microscope equipped with a 100x/1.3
NA oil objective.

Results and Discussion
Identification of cell lines expressing Rab27b—Given the previously reported roles of
Rab27a and Rab27b proteins in exosome release and the known role of Rab27a in promoting
exocytosis of lysosome related organelles in pigment containing cells, we wondered whether
these proteins might selectively identify MVBs destined for exocytosis. We focused our analysis
on Rab27b because of the availability of a rabbit polyclonal antibody (purchased from SySy) that
clearly and robustly recognizes endogenous Rab27b by immunofluorescence. We first assessed
specific immunostaining in three cell lines that we previously characterized for their ability to
release exosomes. Of these, two cell lines displayed distinct patterns of Rab27b staining – the
breast adenocarcinoma MCF-7 and glioblastoma U87 (Figure 3-1). The osteoscarcoma-derived
U2OS cell line did not display specific Rab27b immunostaining, which was expected based on
previous proteomics studies in these cells (12) (data not shown).
MCF-7 and U87 cells exhibited different distribution of Rab27b which are likely
attributable to the cells’ specific phenotypic identity. In epithelial MCF-7 cells, Rab27b staining
was most evident at the cell periphery that is not in contact with an adjacent cell (Figure 3-1, A).
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In order to further define the identity of the Rab27b positive compartments, I costained MCF-7
cells for Rab27b and the late endosome/lysosome/exosome marker CD63. While the majority of
CD63 is present on compartments distributed throughout the cytoplasm, a distinct subset of
CD63 immunostaining overlapped with Rab27b (Figure 3-1, A). This suggests that the
compartments marked by Rab27b in these cells are endosomal in nature and may represent
MVBs that give rise to exosomes. The somewhat polarized distribution of Rab27b in MCF-7
cells is strikingly reminiscent of that observed in acinar lacrimal gland epithelia where it
localizes to apical secretory vesicles (13). MCF-7 cells form multicellular polarized spheroids
with a central lumen when grown in 3D matrix (14). In the future, MCF-7 could provide a
system in which to study polarized exosome secretion.
In mesenchymal U87 cells we saw clearly distinct Rab27b positive organelles localized
throughout the cell (Figure 3-1B). Intriguingly, all Rab27b marked organelles also contained
CD63, while only a subset of CD63 marked organelles were positive for Rab27b (Figure 3-2, A).
The consistent presence of CD63 indicated that Rab27b marked compartments were likely to
represent MVBs. I further characterized the Rab27b marked organelles by immunostaining for
markers of other endocytic organelles. EEA1 is a marker for early endosomes, and showed no
overlap with Rab27b indicating that Rab27b does not recruit to early endosomes in these cells
(Figure 3-2, B). LBPA is another marker of MVBs, but we found no overlap between LBPA and
Rab27b (Figure 3-2, C). This observation is consistent with previous reports that LBPA is
present on a subpopulation of MVBs targeted for degradation and is absent from exosomes (3,
15). These observations demonstrate that Rab27b marks a distinct set of organelles that these
organelles may correspond to the elusive secretory MVB.
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Changes in organelle pH enhance Rab27b recruitment—We wondered what might be
different between CD63 labeled MVBs that are Rab27b positive versus those that are not. Given
that the contents of secretory MVBs (i.e. exosomes) are not degraded, we hypothesized that pH
could be a distinguishing factor. To test this question, we treated cells with Lysotracker Red,
which specifically labels acidic organelles, followed by aldehyde fixation and immunostaining
for Rab27b and CD63. We found that Lysotracker labeled a significant proportion of CD63
positive organelles. However, those marked by both CD63 and Rab27b did not contain
Lysotracker, suggesting that Rab27b localized to non-acidic endosomes (Figure3-3). This
observation led us to hypothesize that pH is a factor contributing to Rab27b recruitment. To test
this idea we treated cells with the weak base chloroquine to neutralize acidic organelles and then
immunostained for CD63 and Rab27b. We observed a remarkable increase in the number and
size of Rab27b/CD63 positive vesicles (Figure3-4, A and B). These observations support the
notion that endosomal pH contributes to regulation of Rab27b recruitment.
Enhanced Rab27b recruitment in response to increased endosomal pH has several
exciting implications. First, this finding suggests that secretory MVBs in U87 cells are less acidic
than those MVBs likely directed for degradation. Second, it indicates plasticity in MVB fate.
Endosome neutralization perturbs degradation in lysosomes where activity of resident proteases
requires low pH. Rab27b recruitment to facilitate exocytosis could be a compensatory
mechanism to prevent accumulation of normally degraded material. Our results are in agreement
with other studies that show upregulated exosome secretion in response to lysosome inhibitors
such as bafilomycin (16). One complication in interpreting the lysotracker staining is the
questionable maintenance of formaldehyde fixed lysotracker after cell permeabilization.
However, the fact that Rab27b did not mark observable lysotracker positive organelles taken
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with increased Rab27b recruitment/number of organelles strongly suggests that non-acidic pH is
a characteristic of exocytic MVBs that could be important in regulating Rab27b recruitment.
How the cell senses endosome neutralization is an important question. To this end, a
transient receptor potential (TRP) calcium channel on the lysosomal membrane was identified as
a key factor in regulating secretion after lysosome neutralization by uropathogenic E. coli (17).
Notably, Rab27 marks these secretory compartments, and the calcium sensor synaptotagmin VII
is involved. Thus, it is possible that pH neutralization triggers lysosomal calcium efflux to
promote exocytosis.
As discussed above, Rab recruitment to membranes is regulated by the coordinated action
of GEFs and GAPs. Furthermore, Rab27 GTP cycling is important for diverse secretory
processes (8, 13, 18, 19). Rab GDP dissociation inhibitor (GDI) also controls Rabs, including
Rab27b, by binding the Rab in its GDP locked conformation to block nucleotide exchange (20).
Each of these regulatory components is an obvious candidate for further investigation into how
organelle pH signals Rab27b recruitment.
In conclusion, MVBs have long been thought of as intermediate organelles en route to
lysosomal degradation. Current research has unveiled the complex nature and diverse fates of the
MVB. Here we extend on these concepts by showing that a subset of MVBs in the U87 cell line
may be marked for exocytosis by recruitment of Rab27b. Our discovery that Rab27b
preferentially localizes to Lysotracker negative CD63 containing organelles and that neutralizing
pH dramatically increases the overall level of Rab27b recruitment raises the intriguing question
of which regulatory components are responsive to organelle pH. Future studies should be aimed
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at discerning the regulation of Rab27b recruitment by GEFs, GAPs and GDI in response to
changes in endosomal pH.
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A.
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U87
Rab27b
CD63

FIGURE 3-1. Rab27b localizes to endosomes in different cell types. A, B, Widefield fluorescence microscopy images of MCF-7 cells (A) or U87 cells (B) stained for Rab27b and CD63 as described in Methods.
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FIGURE 3-2. Rab27b localizes to a subset of CD63+ endosomes in U87 cells. Maximum intensity
projections from confocal Z-series of U87 cells immunostained with the indicated antibodies as described
in Methods. A, Rab27b and CD63 costains. White boxes show regions enlarged in insets. Structures with
both Rab27b and CD63 staining are indicated by arrows. Structures with only CD63 are indicated by
arrowheads. B, Rab27b and LBPA immunostaining shows little to no overlap. C, Rab27b and EEA1
immunostaining shows little to no overlap.
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Rab27b

CD63

Lysotracker

FIGURE 3-3. Rab27b markes non-acidic endosomes. Images are single confocal planes. U87 cells were
treated with Lysotracker Red for 30min before aldehyde fixation and immunostaining.DMSO. White
boxes indicate regions enlarged in insets. Structures with CD63+/Rab27b+/Lysotracker- staining are
indicated with arrowheads. Structures with CD63+/Rab27-/Lysotracker+ staining are indicated with
arrows.
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chloroquine
FIGURE 3-4. Neutral endosome pH enhances Rab27b recruitment. Images are maximum intensity
projections of confocal Z-series. A, B, U87 cells where treated with PBS (A) or chloroquine (B) for 4 hrs
before immunostaining for Rab27b and CD63.

118

Chapter 4
Preliminary data and future directions
4.1 CD63 and CD9 as markers for distinguishing exosomes versus
ectosomes
EVs enriched for either CD63 or CD9 are to some extent physically separable (Figure 21, E). The data presented in Chapter 2 indicate that CD9 is primarily released on ectosomes. The
size of plasma membrane derived vesicles is reported to range from ~150-1000 nm and thus the
lower size limits overlap with that of exosomes. The methods we employed to isolate EVs
include steps to clear large vesicles (i.e. centrifugation at 10,000 x g and/or filtration through
0.2µm pores). Despite these precautions we cannot exclude the possibility that larger vesicles are
present in the material pelleted at 100,000 x g. We therefore analyzed 100k EVs by nanoparticle
tracking. The results of this analysis indicated that the majority of EVs were <200nm with a
mean size of 132±7.1nm and a mode of 100±5.5nm (Figure 4-1). Because our preparations
contain a mixture of both EV types, these results imply that ectosomes bearing CD9 are not
drastically different in size from exosomes bearing CD63. These data support the notion that
EVs collected by size-based methods represent a mixture of exosomes and ectosomes.
It is clear that the steady state subcellular distribution of these tetraspanin proteins differs
(Figure 2-1), indicating that they do not co-assemble into stable microdomains. An interesting
question arising from this observation is whether tetraspanins actually co-assemble in vivo as
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opposed to detergent solubilized membranes, in which multiple heteromeric tetraspanintetraspanin interactions have been reported (1).
Endocytic trafficking of CD63 is regulated by C-terminal YXXΦ motif that binds to
clathrin adaptor proteins. In contrast, CD9 does not have this motif and is largely restricted to the
plasma membrane. Despite their differential steady-state distributions, both proteins cycle
through the endocytic system. Because of this dynamic trafficking, CD9 does end up on
exosomes and CD63 on ectosomes (2, our results, Chapter 2). Both CD63 and CD9 can be
tagged on their cytoplasmic N-termini without affecting trafficking or known interactions with
cellular proteins and function. In order to probe the segregation and/or overlap between these
markers on individual vesicles I generated HEK293 cell lines that stably express different
combinations of mCherry-CD63, EGFP-CD63 and EGFP-CD9 proteins. Confocal images are
shown in Figure 4-2 and demonstrate that each fusion protein mimics the localization of the
endogenous protein (Figure 4-2, A-D).
The level of overexpression was determined by comparing immunoblots of each cell line
to those of the parent cell line (Figure 4-3, A). In order to demonstrate that the tetraspanin
fusions are released on EVs, I harvested EVs from culture media using the PEG/ConA protocol
described in Chapter 2. Both total cell protein and EVs were subjected to immunoblotting with
antibodies against GFP or mCherry. Importantly, the level of fluorescent protein released on EVs
correlates with the relative expression level in the cells from which they derived (Figure 4-3, B).
Fluorescence Cross-correlation Spectroscopy (FCCS) is attractive as a future application
utilizing these cells to directly monitor the degree of CD63 and CD9 segregation on different
populations of EVs. FCS measures fluctuations in fluorescence as particles in Brownian motion
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pass through a ~1 fl confocal volume. If two fluorophores are located on the same EV,
fluorescence fluctuations in two colors cross-correlate enabling FCCS. In future studies, it will
be interesting to use EVs collected from these cell lines to assess the degree of separation of
these proteins on EVs. If we see coincidence between the signals, we can determine what
percentage of EVs have one or the other label. EVs from the mCherry-CD63 and GFP-CD63 coexpressing cells will be an important control for positive cross-correlation. In addition, EVs from
cells individually expressing mCherry-CD63 and GFP-CD9 would be mixed together as a
control for negative correlation. Hence, the cell lines described above will be important tools for
assessing the relative ratios of CD63 and CD9 in different EV populations.

4.2. Extended analysis of EV cargo proteins
In Chapter 2, our analysis of EV secretion focused primarily on tetraspanins (CD63 and
CD9) as well as the adaptor protein syntenin-1, which associates with CD63. These proteins are
clearly enriched in EVs relative to total cell lysates. Furthermore, they have each been implicated
in different aspects of EV biology. We also assessed a sample of miRNA cargo as well as a
general membrane marker (GPI-mCherry). Our results demonstrated that inhibition of VPS4
resulted in decreased EV release. Notably, however, EV release was not completely abrogated.
During the course of my thesis work, I monitored the fate of several other candidate EV proteins.
In contrast to the tetraspanins, I observed variable reproducibility in the effects of inhibiting
VPS4 on the recovery of these proteins. Much of this may be due to challenges associated with
sample handling and/or lack of robust antibodies; therefore, we could not comment on their
relevance in that unit. However, these results could reflect complexities in the cohort of
mechanisms at play during EV biogenesis and general membrane trafficking. A number of
reproducible changes are noteworthy and merit further study. In particular, ESCRT-III proteins
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were readily recovered in EVs released after VPS4 inhibition. The resulting changes in their
recovery may provide evidence for the direct role of VPS4 and ESCRT-III in the membrane
fission process that generates EVs. The following section describes these changes and discusses
their potential implications in different aspects of EV biogenesis.
VPS4 inhibition alters EV protein composition—Hsc70 is an often-cited EV-associated
protein. During the course of my thesis work I found that Hsc70 was modestly, albeit
reproducibly, decreased in EVs released by cells expressing VPS4EQ (Figure 4-3, A).
Preliminarily, we found that Hsc70 was not particularly enriched or de-enriched in EVs
compared to cellular levels (data not shown). Hsc70 is a soluble heat shock protein that functions
in proteostasis. It is implicated in regulating misfolded protein responses, autophagy and even
direct sorting to exosomes (3, 4). Its presence in EVs is likely directly connected to these
functions. Therefore, the mechanism by which VPS4EQ expression affects its incorporation into
EVs is likely to be an interesting avenue for further investigation.
GSK3β is another soluble protein that we monitored in EVs released from various cell
types. Motivation for focus on this cargo comes from the β-catenin dependent sequestration of
GSK3β into MVBs following stimulation of cells by Wnt (5). In resting conditions, GSK3β was
consistently de-enriched in EVs. In contrast to the EV proteins discussed thus far, we found that
cells expressing VPS4EQ released greater concentrations of GSK3β compared to control cells
(Figure 4-3, B).
LAMP1 and LAMP2 are single-pass transmembrane proteins primarily associated with
the limiting membrane of late endosomes/lysosomes. Our preliminary inspection of EVs released
by different cell types demonstrated that these proteins, while detectable in EV preparations, are
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de-enriched relative to their cellular expression levels (data not shown). This finding is in
agreement with those of several EV characterization studies. Similar to our findings for GSK3β,
LAMP2 levels were increased in EVs recovered from cells expressing VPS4EQ (Figure 4-3, C).
Taken together, it seems likely that while our results show that VPS4 inhibition reduced EV
numbers it also altered the protein profile of EVs that were released from these cells. This effect
may result from parallel inhibition of both EV biogenesis and other pathways involved in
proteostasis
Altogether, the changes in EV protein content elicited by VPS4 inhibiton may reflect
broader effects on membrane trafficking within the endosomal network. For example, there have
been hints that regulation of lysosome homeostasis are linked to exosome secretion (6, 7). VPS4
inhibition perturbs lysosomal flux and triggers autophagy (8, 9). Inhibition of lysosomal function
with the proton pump inhibitor bafilomycin has been shown to enhance exosome release (10).
These results underscore the potential for plasticity in MVB fate in terms of lysosomal
degradation versus extracellular release. Such observations warrant further investigation into the
specific steps at which VPS4 and ESCRT-III act during trafficking of EV cargo proteins.
ESCRT proteins are incorporated into EVs—The data presented in Chapter 2 show that
inhibition of VPS4, the master regulator of ESCRT-III disassembly, inhibits release of both
exosomes and ectosomes. Others have similarly implicated different components of the ESCRT
machinery in both exosome and ectosome biogenesis (11-15). Importantly, both vesicle types
share a common physical requirement for membrane fission to separate the vesicle and the
membrane from which it derived. Given this requirement, ESCRT-III and factors involved in its
assembly and disassembly are the strongest candidates for this process.
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Notable among studies of all EVs is that ALIX and Tsg101 are broadly cited as markers
of EVs and especially exosomes. The implication is that these proteins, which are important
nucleators of ESCRT-III assembly, are directly involved in EV biogenesis. However, efforts to
directly connect this function to EV production have yielded variable results (12, 13, 16, 17).
Nonetheless, the common presence of these proteins in EVs from various sources supports the
notion that ESCRT is important for EV formation.
A concern when interpreting the content of EV preparations is the possibility of crosscontamination by large polymeric protein structures as well as protein aggregates. To confirm
that extracellular ESCRT-III is indeed associated with membranes, we subjected 100k EV pellets
to sucrose gradient floatation (Figure 4-5, A). This analysis clearly showed that the major
ESCRT-III protein CHMP4A is membrane associated. A recent study done in collaboration with
our lab employed quantitative tandem-mass-tag proteomics to compare EVs obtained by
differential ultracentrifugation either directly or after Opti-prep gradient floatation in order to
discern vesicle-associated proteins from other contaminants (18). In agreement with our findings
using sucrose gradients, several ESCRT-III members were enriched in the Opti-prep fractions.
Notably, we found elevated levels of CHMP4A (ESCRT-III) in EVs produced by cells in which
VPS4 was inhibited (Figure 4-5, B). The role of VPS4 in ESCRT-III polymer disassembly is
well established. Hence, this finding suggests that blocked disassembly causes ESCRT-III
subunits to accumulate within EVs. Thus, more ESCRT-III was recovered despite the fact that
fewer EVs were released. This finding may provide clues concerning the importance of ESCRTIII disassembly during EV biogenesis.
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Methods
Antibodies, Plasmids and reagents—Antibodies used include mouse monoclonal
antibodies against CD63 (Dev Biostudies (H5C6)), a monoclonal antibody against LAMP1 (Dev
Biostudies H4A3), a polyclonal antibody against GSK3β (ProteinTech 22104-1-AP), a
polyclonal antibody against CHMP4A (19), and a monoclonal antibody against Hsc70 (Sigma
Aldrich H5147).Secondary antibodies were conjugated to horseradish peroxidase for
immunoblotting (ThermoFisher), HEK293TREx cells were maintained as described in Chapter
2.
pmCherry-CD63 was described in Chapter 2 and was used to generate
pCDNA4.1mCherry-CD63 using NdeI and BamHI sites. pEGFP-CD9 was described in Chapter
2. Cells were transfected using Lipofectamine 2000 followed by selection with 500µg/ml G418
and/or 100µg/ml zeocin.
EV collection and sucrose gradients—EV collection by PEG/ConA or differential
centrifugation was performed as described in Chapter 2. EV pellets collected by differential
centrifugation were suspended in 1.25 ml of 73% sucrose buffer in 20mM HEPES pH7.4. A
discontinuous sucrose gradient was layered over this by applying 3 ml of 65% and finally 1.25
ml of 10% sucrose in 20mM HEPES pH7.4. After centrifugation at 34,000 × g for ≥14 hr, 500
µl fractions were taken from the top. 20 µl of each fraction was used for SDS-PAGE and
immunoblotting.
SDS-PAGE and immunoblotting—Samples were boiled in SDS-PAGE sample buffer
(2% SDS, 60mM Tris pH 6.8, 0.01% bromophenol blue, 10% glycerol) with or without 1% βmercaptoethanol for 5 min and spun for 2 min at 21,000 × g. CD63 immunoblotting required
non-reducing conditions. Proteins were separated on 10% gels followed by transfer to
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nitrocellulose. Membranes were blocked and probed in TBS, 0.05% Tween and 5% nonfat dry
milk. Blots were imaged on a ChemiDoc MP imaging system (Bio-Rad).
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Chapter 4 Figures
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FIGURE 4-1. NanoSight particle tracking analysis of HEK293 EVs. EVs from HEK293 cells where
isolated by differential centrifugation as described in Methods. The pellet was resuspended in HEPES
buffer and a 1:500 dilution was applied to the NanoSight chamber. Average size = 132±7nm. Mode size =
100±5.5nm. Standard deviation = 58±6nm.
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FIGURE 4-2. HEK293 cells expressing fluorescent tetraspanins. Images are single confocal planes. A,
Cells expressing only GFP-CD9. B, Cells expressing only mCherry-CD63. C, Cells co-expressing GFPCD9 and mCherry-CD63. D, Cells co-expressing GFP-CD63 and mCherry-CD63. Scale bar = 10µm.
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FIGURE 4-3. Fluorescently tagged tetraspanins are released on EVs. A, Cells from Figure 4-2 were
solubilized as described in methods. Equal concentrations of whole cell protein from each cell line were
immunoblotted for tetraspanins. B, EVs produced in 24hr by each cell line were collected by PEG/ConA.
Volume of solubilized EVs was normalized to the total cellular protein concentrations. Equal concentrations of whole cell protein (Lysate) and equal volumes of EVs (PEG/ConA EVs) were immunoblotted
with antibodies against GFP or mCherry.
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FIGURE 4-4. VPS4 inhibition alters EV protein composition. (A-C) EVs from VPS4EQ expressing cell
over were harvested by differential centrifugation or PEG/ConA as described in methods. The EV resuspension volumes were normalized to the total protein concentration of the cells from which they derived.
Equal concentrations of cellular protein and equal volumes of EV protein were immunoblotted with the
indicated antibodies.
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FIGURE 4-5. ESCRT-III is incorporated into EVs. A, EVs from SKBR3 cells were collected by differential centrifugation and floated into a sucrose gradient as described in Methods. Fractions were immunoblotted for CHMP4A and CD63. B, EVs from VPS4EQ expressing cells were harvested by differential
centrifugation. The EV resuspension volumes were normalized to the total cellular protein concentration.
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Chapter 5
Summary and Discussion
Summary of the Thesis
The extracellular environment is an important player in modulation of cellular activities.
This statement is exemplified by our understanding of signaling processes requiring cell
interactions with other cells, extracellular matrix, secreted soluble ligands, and hormones. As
discussed above, EVs are emerging as intriguing components of the extracellular milieu which
an increasing body of evidence points to as signaling units capable of eliciting phenotypic
responses in the cells with which they come into contact. While evidence supports the capability
of EVs to cause such changes, the specific roles proposed for exosomes in cell-cell signaling are
difficult to test given that so little is known about their biogenesis.
A major challenge that limits investigations of EV biology is the lack of simple methods
to reproducibly collect and quantify EVs. The most common method for concentrating EVs from
culture medium is differential centrifugation (Chapter 1). We used typical procedures to collect
EVs released from cultured cell lines by differential centrifugation followed in some cases by
flotation into sucrose gradients (Chapter 2). We found that proteins characteristic of EVs were
recovered in differing amounts from conditioned media, depending on the cell line studied and
consistent with previously reported differences in EV production. However, differential
centrifugation requires relatively large quantities of cells and/or long incubation time. These
requirements preclude acute analysis of EV production and limit the repertoire of manipulations
that can be tested since many pharmacological treatments are toxic to cells after long times. To
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address this problem I developed a protocol for concentrating EVs from small volumes of culture
medium using polyethylene glycol precipitation followed by lectin affinity isolation (Chapter 2).
At the time I began my thesis, mechanisms of EV biogenesis were only beginning to be
investigated. Given the topology of EV budding, the MVB origin of exosomes, and the wellcharacterized roles of ESCRT in MVB biogenesis, ESCRT proteins were commonly invoked as
cellular machinery likely to be involved in generating EVs. However, seminal work by Trajkovic
and colleagues suggested an ESCRT-independent mechanism for budding of proteolipid protein
into the MVB lumen prior to exocytosis (1). This gave rise to the concept that ESCRTs were
unlikely to be generally required for forming the MVBs that give rise to exosomes. Over the
course of my thesis work, studies from other groups have taken different approaches to address
the question of ESCRT function in EV biogenesis with varying results limited by both the
techniques and the complexity of ESCRT function in endosomal maturation
Our interest in studying EV biogenesis grew out of the lab’s interest in how ESCRT-III
and Vps4 work together and with other factors to promote vesicle (and virus) biogenesis and
release. If ESCRT-III and Vps4 are directly responsible for creating ILVs within multivesicular
bodies, a straight-forward prediction was that they should be necessary for exosome formation
(and therefore release). Additionally, as part of the lab’s effort to connect ESCRT-III filament
structure to function in vesicle biogenesis we explored the localization and structure of ESCRTIII filaments stabilized by depleting Vps4 and found spirals likely to represent “scars” left behind
by released vesicles on both endosomes and the plasma membrane (2). Together with the known
role of ESCRT-III in viral particle budding from both the plasma membrane and the MVB, these
observations led us to suspect a general involvement of ESCRT-III at both sites.
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Attempts to assess ESCRT-III role in EV biogenesis have typically relied on siRNAmediated depletion of individual ESCRT-III subunits. Interpreting results of these studies is
complicated, since ESCRT-III is a dynamic polymer comprised of multiple closely related
subunits, the precise stoichiometry of which is largely unknown. Furthermore, studies on
ESCRT-III function in other biological processes suggest that not all subunits are required in
each process and further that the function of some may be redundant. To broadly and efficiently
inhibit ESCRT-III function, I employed the dominant-negative, ATPase-defective Walker B
mutant of VPS4 (here referred to as VPS4EQ), which is the AAA+ ATPase master regulator of
ESCRT-III disassembly that is required for all ESCRT-dependent processes. Using cell lines in
which VPS4EQ is inducibly expressed, I was able to achieve timely and coordinated inhibition
of ESCRT-III disassembly. I found that this manipulation decreased release of canonical EV
proteins CD63 and CD9 as well as of representative miRNA cargo (Chapter 2). Importantly,
VPS4EQ also reduced the number of membranous vesicles secreted into the culture medium.
The consistent recovery of ESCRT proteins by EV proteomics is a primary impetus for
investigating their role in EV biogenesis. Our finding that ESCRT-III proteins were more
concentrated in EVs released by VPS4EQ expressing cells, despite the decrease in vesicle
number, suggests that ESCRT-III polymer disassembly is important for membrane fission during
EV formation.
Cells release two types of EVs that can be defined by their intracellular membrane of
origin. I was intrigued by the contrasting localization of the tetraspanin proteins CD63 and CD9,
which have become widely accepted as markers of exosomes. Indeed, CD63 localizes to
endosomes and is enriched on lumenal vesicles within MVBs (3). In contrast, CD9 localizes
primarily to the plasma membrane (4). Therefore, I hypothesized that CD63 is released on
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exosomes while CD9 marks ectosomes. Using continuous sucrose gradient fractionation I show
that these proteins are present on different populations of physically separable EVs. Further
support for this interpretation came from finding that treating cells with nocodazole to interfere
with MVB trafficking reduced CD63 but not CD9 release. In addition, I characterize serum as a
specific trigger of VPS4-dependent ectocytosis (Chapter 2). Altogether, these findings implicate
VPS4, and by extension ESCRT-III, in biogenesis of both exosomes and ectosomes. In order to
further probe the extent to which CD63 and CD9 segregate on different EVs, I developed and
characterized cell lines expressing these proteins fused to GFP or mCherry in different
combinations.
With specific regard to exosome release, a further mystery is the question of what
distinguishes a MVB destined for exocytosis from one destined for degradation. Currently, the
most well characterized factors involved in the actual trafficking and release of exocytic MVBs
are Rab27a and Rab27b. I have identified Rab27b as a likely marker of exocytic MVBs in U87
cells (Chapter 3). Rab27b localizes to a subset of late endosomes that also contain the exosomal
protein CD63. I have provided evidence that these specialized MVBs are less acidic than
canonically degradative MVBs. Furthermore, endosome pH appears to play a direct role in
recruiting Rab27b since chloroquine neutralization increases both Rab27b endosomes and CD63
release.

Discussion
Understanding ESCRT-III function during EV biogenesis—Current thinking about how
ESCRT-III and VPS4 act to create and release intralumenal vesicles has generally supported a
model in which ESCRT-III filaments spiral on the membrane to surround cargo and eventually
promote membrane buckling, neck constriction, and ultimately membrane fission -- all from the
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cytoplasmic side of the event (5)(6). A difficulty with this model is understanding how the
nucleating component(s) within the nascent particle separate from the spiral that they nucleate.
This has led to some confusion and at least one proposal for how ESCRTs might act from the
other side, assembling (and departing) with a viral particle (and, by analogy, an EV) (Van
Engelenburg et al., 2014). While the data supporting this alternative model for viruses are not
particularly strong (together with a general failure to report/detect appearance of ESCRT-III
factors in released viruses, albeit in decidedly limited numbers of incomplete studies), there is a
major question here. The frequent and enriched recovery of Alix and the entire ESCRT-III/Vps4
machinery in EVs and our data indicating that ESCRT-III disassembly regulates ESCRT-III
concentration in EVs motivates readdressing this question.
ESCRT-dependent ILV formation in yeast requires an initiating ubiquitin signal on cargo
proteins that in turn recruits components of the ‘canonical’ ESCRT pathway ending with
ESCRT-III and Vps4 (7). In the case of viruses, viral structural proteins contain so called ‘late
domain’ motifs that recruit either Tsg101 (ESCRT-I) or Alix to engage and activate ESCRT-III
(8). If ESCRT-III (alone among ESCRT complexes) is involved in EV biogenesis, how is it
recruited? One answer comes from a study of syndecan/syntenin containing exosomes, where
syntenin was found to contain YPxL Alix binding motifs essential for its ability to promote
exosome release (9). By recruiting Alix, syntenin couples cargo and the domain that it forms to
ESCRT-III. The fact that syntenin is frequently present in EVs, binds CD63, and was found to
play a general role in exosome release (9) suggests that it may be an adaptor broadly relevant in
EV formation. Our data are consistent with a role for VPS4/ESCRT-III in syntenin release in
EVs (Chapter 2). ALIX binds directly to CHMP4, and this is the proposed mechanism of
ESCRT-III recruitment during EV biogenesis (10) (9). One way to test this hypothesis could be
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to directly interfere with ESCRT-III polymerization downstream of ALIX-CHMP4 binding.
Furthermore, syntenin is not important for release of several EV proteins including CD9 and
flotillin (11) (9). Future studies should aim at identifying other adaptor molecules capable of
recruiting ALIX to determine if other EVs also depend on ALIX through different mechanisms.
In the future, it will be important to understand whether and/or how ESCRT-III polymerization
directly contributes to proposed mechanisms of EV budding.
Investigating the exocytic MVB—As discussed in Chapters 1 and 3, the machinery
responsible for trafficking, docking, and fusion of MVBS with the plasma membrane includes
small GTPases and their effectors, their regulating GEFs and GAPs, and exocytic SNAREs.
Importantly, however, none of these factors are uniquely responsible for MVB exocytosis but
instead have a variety of other client membranes including lysosomes (12) , lysosome related
organelles (13), and recycling endosomes (14). Physiologic effects associated with depleting any
of these can therefore not be uniquely attributed to a block in EV release. There is clearly still
much to learn about proteins controlling MVB exocytosis for EV release.
In Chapter 3, I focused on Rab27b as a candidate marker for exocytic MVBs in a subset
of cell-types that express this protein. Rab27a expression is high in endocrine pancreas,
intestines, parotid gland, while Rab27b is high in brain, spleen, paralotid, platelets, exocrine
pancrease (13). Elevated Rab27b expression has been connected to bladder cancer, which is in
line with the notion that mis-regulated exosome secretion contributes to cancer progression (15).
However, given that most or all cells secrete exosomes an important question is what factors take
the place of Rab27b when it is not expressed.
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In Chapter 1, I discussed various other small GTPases implicated in exosome secretion
including Rab11, Rab35, Arf6 and RalA/B . Some common threads may provide hints as to how
exosome secretion is regulated in different cell types. One possible explanation is overlap in the
effector molecules that bind to these GTPases. For example, both Rab27 and Rab11 bind to
Munc13-4 to regulate calcium-dependent docking of secretory vesicles to the plasma membrane
(16, 17). Ral GTPases are involved in secretion events along with Rab27 in several systems (18).
Rab27, RalA/B and Rab11 and Arf 6 each interact with subunits of the exocyst complex, which
is broadly implicated in tethering secretory vesicles to the plasma membrane. RalA/B binds Sec5
and Exo84, Rab 11 and Rab27 bind to Sec15 and Arf6 binds to Sec10 (18, 19) (20) (21). It will
be interesting to test the importance of exocyst function during exosome release across different
cell types. Several exocyst subunits bind to phosphoinoitides or possess domains capable of
binding phosphoinositides (22) (23) (24). In particular, PI(4,5)P2 regulates exocyst membrane
association. Interestingly, Rab35 is involved in regulating PI(4,5)P2 levels through its effector
OCRL, which contains an inositol polyphosphate 5-phasphotase domain. Therefore, it is likely
that regulation of phosphoinositides is an important mechanism for recruiting exosome secretion
factors. These observations demonstrate interconnections between different trafficking
regulatory GTPases and highlight factors that may be common regulatory elements during
exosome secretion from different cell types.
Sensitivity of EV detection—A major challenge in studying both EV biogenesis and
function is that the current list of EV-associated material is huge (Choi et al., 2014; Kim et al.,
2015), reflecting the ease with which high throughput –omics techniques can generate data
describing extracellular material collected from any source. While common and abundant
components are repeatedly identified, most of the thousands of other factors present in subsets of
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EV datasets are the result of vesicle heterogeneity (e.g. collected from different cell types,
released in response to different secretory cues, etc.), contamination by other non-EV material
(e.g. other membranes, fragments of dead/dying cells, components of the extracellular matrix, or
non-vesicular secretions), or simply differences in detection limits. Distinguishing among these
explanations is in most cases impractical. Additionally, most studies of cultured cells examine
EVs collected over an extended period of time (often a day or more) because of limitations
imposed by sample handling and detection sensitivity. This averaging of release (over time in
cell culture experiments, and among cell types in body fluids) masks connections to cargopackaging and release-triggering events which again makes it difficult to explore the responsible
molecular machinery. In order to study cellular mechanisms responsible for EV biogenesis and
release, strategies are needed to reduce sample heterogeneity, improve assay sensitivity and
throughput, and provide kinetic and spatial resolution to the analysis of EV release.
In this work, I developed a protocol for isolating heterogeneous EVs from small numbers
of cells after relatively short incubation times (Chapter 2). Methods for monitoring EV release
with much greater temporal resolution are needed for more detailed characterization. The ability
to trigger EV release with serum was critical to my assessment of ectosome release kinetics.
Future studies should be aimed at identifying other EV secretagogues. Growth factors, calcium
ionophores , phorbol esters and lysosomal perturbants are all likely candidates for triggering
release of different EV types (Gennebäck et al., 2013)(Jeppesen et al., 2014; Savina et al., 2003)
(Mittelbrunn et al., 2011)(Savina et al., 2003).
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